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SOMMARIO 
 
INTRODUZIONE 
Le cefalee sono patologie frequenti in età pediatrica, tendono ad avere decorso cronico e 
spesso comportano un notevole peggioramento della qualità di vita. Identificare eventuali 
cause o fattori scatenanti potenzialmente trattabili è un obiettivo primario nella gestione del 
paziente cefalalgico. Recenti evidenze indicano come la cefalea rappresenti uno dei sintomi 
maggiormente prevalenti nel contesto di patologie glutine-correlate, in particolare nella 
Sensibilità al glutine non celiaca (NCGS). Tuttavia la prevalenza di NCGS nei pazienti 
cefalalgici in età pediatrica, così come i meccanismi etio-patogenetici della cefalea nell’ambito 
di NCGS, sono per lo più sconosciuti. 
SCOPI DELLO STUDIO 
Gli obiettivi dello studio sono: 1) indagare la prevalenza ed il quadro clinico di NCGS in una 
coorte di pazienti in età pediatrica che presentano markers sierologici di possibile sensibilità 
al glutine (anticorpi anti-gliadina nativa – AGA); 2) valutare il profilo di espressione genica in 
cellule mononucleate del sangue periferico (PBMCs) raccolte in pazienti con NCGS e 
cefalea; 3) misurare nel siero dei pazienti cefalalgici alcuni mediatori solubili identificati 
mediante l’analisi del profilo di espressione genica di PBMCs e valutare l’eventuale positività 
per anticorpi anti - Tranglutaminasi 6 (TG6), markers di patologie neurologiche glutine-
dipendenti. 
PAZIENTI E METODI 
Sono stati considerati per il reclutamento i soggetti di età inferiore ai 18 anni valutati per 
cefalea nel periodo 1/03/13 – 31/07/15 presso l’Unità di Neuropsichiatria Infantile 
dell’Azienda Ospedaliera Universitaria Integrata di Verona. I criteri di inclusione erano i 
seguenti: 1) diagnosi di cefalea primaria posta secondo i criteri ICHD III-beta; 2) accettare 
indagini diagnostiche comprendenti dosaggio di IgA totali, AGA IgG ed IgA, anticorpi anti-
tranglutaminasi 2 IgA (TGA), IgE specifiche per grano, glutine, gliadina. Una volta acquisito 
il consenso informato, i pazienti sono stati sottoposti a valutazione di esame 
emocromocitometrico, profilo biochimico, indici di flogosi, studio della funzionalità epatica, 
renale e tiroidea, dosaggio di IgA totali, TGA, AGA IgA e IgG. Sono stati esclusi i pazienti 
che presentavano: cefalea secondaria o nevralgia cranica; trattamenti introdotti o modificati 
negli ultimi 2 mesi; deficit di IgA parziale o totale, secondo i riferimenti per età; soggetti 
positivi per TGA (sospetta celiachia) o IgE specifiche per grano, glutine, gliadina (sospetta 
allergia al grano); riscontro bioptico duodenale di enteropatia (indagine a completamento 
dell’iter diagnostico effettuata nei soggetti con riscontro di AGA-positività). Come da attuale 
protocollo diagnostico per sospetta Sensibilità al glutine non celiaca, i soggetti AGA-positivi 
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sono quindi stati sottoposti ad una dieta strettamente priva di glutine (DPG) per 3 mesi, con 
successiva reintroduzione di glutine nella dieta per ulteriori 3 mesi (gluten challenge). I 
soggetti AGA-negativi hanno proseguito una dieta a normale contenuto di glutine. 
L’andamento della cefalea è stato valutato al reclutamento e nel corso del follow-up mediante 
somministrazione di scale standardizzate e questionari specifici per rilevazione di disturbi 
emotivi e comportamentali in età pediatrica.  
Per i pazienti con conferma diagnostica di NCGS è stata effettuata l’analisi dell’espressione 
genica in PBMCs raccolte in fase attiva di malattia. In relazione ai dati di espressione genica, 
sono stati scelti CTLA-4 solubile (sCTLA-4) e gp130 solubile (sgp130) come mediatori da 
dosare nel siero dei pazienti cefalalgici. E’ stato inoltre effettuato il dosaggio sierico del 
mediatore CD25 solubile (sCD25), selezionato come marker di attivazione T-linfocitaria, e 
degli anticorpi TG6 IgA ed IgG.  
RISULTATI 
Sono stati reclutati 17 pazienti con emicrania o cefalea muscolo-tensiva: 11 soggetti AGA-
positivi (4 maschi, 7 femmine; età media 10,6 anni; range d’età 7,9-12,5 anni), 6 soggetti 
AGA-negativi (2 maschi, 4 femmine; età media 11,6 anni; range d’età 9,1-13,8 anni). Tutti i 
soggetti AGA-positivi sono stati sottoposti a biopsia duodenale in corso di dieta a normale 
contenuto di glutine e nessuno ha avuto riscontro istologico di enteropatia. Successivamente 
i soggetti AGA-positivi hanno effettuato dieta aglutinata a scopo diagnostico seguita da 
challenge con glutine. Sei pazienti AGA-positivi su 11 (55%) hanno quindi ricevuto la 
diagnosi definitiva di NCGS, in relazione al miglioramento clinico in corso di DPG e 
ricaduta in fase di challenge.  
Non sono emerse peculiarità cliniche in merito alle caratteristiche della cefalea nei pazienti 
con NCGS. Sintomi gastrointestinali sono risultati più frequenti in questi pazienti (50% dei 
soggetti) rispetto ai soggetti AGA-positivi non-NCGS o ai soggetti AGA-negativi. Sintomi 
extra-intestinali (astenia, tono dell’umore depresso, anemia, febbricola persistente, dermatite, 
scarso accrescimento) sono risultati più rappresentati nei soggetti AGA-positivi, ma non utili 
nel discriminare tra questi i soggetti con NCGS. 
Tre soggetti AGA-positivi su 11 (27%), ovvero 1/6 (17%) AGA-positivi con NCGS e 2/5 
(40%) AGA-positivi non-NCGS, presentavano anche anticorpi TG6 IgA. Nessuno dei 
soggetti AGA-negativi ha avuto riscontro di TG6 IgA. Nessun soggetto nei 3 gruppi è 
risultato positivo per anticorpi TG6 IgG. I soggetti con titoli elevati di anticorpi TG6 IgA 
non hanno mostrato miglioramento clinico nel corso dei 3 mesi in dieta aglutinata. 
Il profilo di espressione genica in PBMCs di pazienti con NCGS ha documentato up-
regolazione, in fase attiva di malattia, di numerosi geni correlati ad attivazione del 
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compartimento T- e B-linfocitario, nonché up-regolazione di geni correlati al compatimento 
Th17 e geni con signature di Interferone tipo I.  
Al reclutamento, in dieta a normale contenuto di glutine, i livelli sierici di sCTLA-4 sono 
risultati più elevati nei soggetti AGA-positivi rispetto agli AGA-negativi, con differenza 
statisticamente significativa (livello medio 14.46±3.74 ng/ml vs 0.53±0.67 ng/ml; p=0.001). 
In corso di dieta aglutinata si è osservata una riduzione dei livelli di sCTLA4 in tutti i soggetti 
AGA-positivi, anche se la diagnosi di NCGS non è stata confermata in alcuni di essi. La 
differenza nei livelli di sCTLA-4 al reclutamento e dopo DPG è risultata statisticamente 
significativa nei pazienti con NCGS confermata (livello medio 14.46±3.74 ng/ml vs 
4.28±3.46 ng/ml; p=0.036). 
I livelli sierici di sgp130 non sono risultati significativamente differenti al momento del 
reclutamento nei soggetti con NCGS, quando confrontati con i soggetti AGA-positivi non-
NCGS o AGA-negativi, né si è potuto osservare un significativo effetto della dieta aglutinata 
sul livello sierico di questo mediatore. Analogamente, i livelli sierici di sCD25 sono risultati 
simili nei 3 gruppi di pazienti.   
CONCLUSIONI 
Un sottogruppo di pazienti in età pediatrica con cefalea primaria soddisfa i criteri clinici per 
NCGS.  
I dati sperimentali di analisi dell’espressione genica sono suggestivi di una condizione 
immuno-mediata con signature “Interferone di tipo I”, tipicamente riscontrata in malattie 
autoimmuni. Elevati livelli sierici di sCTLA-4 in soggetti AGA-positivi potrebbero costituire 
un ulteriore indizio di sensibilizzazione al glutine e coinvolgimento della risposta immunitaria 
adattativa. 
Il riscontro di anticorpi anti-TG6 nel siero di pazienti AGA-positivi con cefalea potrebbe 
essere predittivo di un’insoddisfacente risposta clinica alla dieta aglutinata perseguita per soli 
3 mesi, giustificando pertanto un tentativo di trattamento dietetico più prolungato, 
verosimilmente di 6-12 mesi, come attualmente raccomandato per i soggetti con sospetta 
atassia da glutine positivi per anticorpi anti-TG6. 
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ABSTRACT 
 
BACKGROUND 
Headaches frequently occur in childhood, often with a relevant burden on quality of  life. 
The identification of  any underlying treatable causes or precipitating factors should be a 
primary endpoint in headache management. Headache is one of  the most frequently 
reported complaints in patients with gluten-related disorders, particularly Non-celiac Gluten 
Sensitivity (NCGS), although prevalence of  NCGS in headache patients in childhood is 
unknown. Moreover, etio-pathogenetic bases for headache in NCGS are poorly understood. 
AIMS OF THE STUDY 
The study aimed: 1) to explore the prevalence and the clinical picture of NCGS in a cohort 
of pediatric headache patients with serological markers of gluten sensitivity (native anti-
gliadin antibodies - AGA); 2) to analyze gene expression profiles in peripheral blood 
mononuclear cells (PBMCs) from pediatric headache patients with NCGS; 3) to validate 
some of gene array results by the measurement of soluble mediators in sera of patients, and 
to determine serum levels of Tranglutaminase 6 (TG6) antibodies, markers of neurological 
gluten-related disorders. 
PATIENTS AND METHODS 
Patients aged <18 years and evaluated for headache at the Child Neuropsychiatry Unit, 
University Hospital of Verona, Italy, in the period 1/03/13 – 31/07/15 were considered for 
recruitment in the study. Inclusion criteria were: 1) to be diagnosed with a type of primary 
headaches according to the ICHD III-beta criteria; 2) to accept determination of total IgA, 
AGA IgG and IgA, anti-tranglutaminase 2 IgA antibodies (TGA), and specific IgE to wheat, 
gluten, gliadin on serum samples. After informed consent, patients were investigated with a 
complete blood count, biochemical analyses and evaluation of liver, renal and thyroid 
function and dosage of total IgA and TGA. Patients were excluded if one of the following 
conditions occurred: fulfilled criteria for secondary headaches or cranial nerve neuralgias; 
ongoing treatments for headache introduced or modified less than 2 months before; total or 
partial IgA deficiency, according to reference values for age; to have tested positive for TGA 
(suspected diagnosis of celiac disease) or IgE to wheat, gluten, gliadin (suspected diagnosis 
for wheat allergy); presence of enteropathy at duodenal biopsy (performed only in AGA-
positive patients). Determination of AGA was performed. According to the diagnostic 
algorithm for NCGS, AGA-positive patients underwent a 3 months – period on gluten-free 
diet (GFD) followed by reintroduction of dietary gluten for 3 months (gluten challenge). 
AGA-negative patients continued on their normal, gluten-containing diet. The headache 
clinical course was evaluated by means of standardized scales and questionnaires. 
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PBMCs were collected from NCGS patients in active phase of the disease for gene 
expression profiling. 
Based on results of gene expression profiling, soluble CTLA-4 (sCTLA-4) and soluble gp130 
(sgp130) were chosen to be determined in sera of headache patients. Soluble CD25 (sCD25), 
chosen as a biomarker for T lymphocyte activation, and TG6 IgA and IgG were also 
measured in sera.  
RESULTS 
Seventeen patients were recruited with migraine or tension-type headache: 11 subjects (4 
males, 7 females; mean age, 10.6 years; age range, 7.9-12.5 years) tested positive for AGA, 6 
children (2 males, 4 females; mean age, 11.6 years; age range, 9.1-13.8 years) were AGA-
negative. All AGA-positive patients had duodenal biopsy on gluten-containing diet: None of 
the subjects displayed histological signs of enteropathy. AGA-positive patients underwent 
GFD followed by gluten challenge. Six out 11 AGA-positive patients (55%) received the 
diagnosis of NCGS, due to clinical improvement on GFD and relapse on gluten challenge.  
As for clinical picture, no headache features or migraine-associated syndromes resulted to be 
typical of NCGS patients. Gastrointestinal symptoms occurred more frequently in NCGS 
patients (50%) than in other patients. Extra-intestinal symptoms (fatigue, depression, anemia, 
long-lasting low-grade fever, dermatitis, failure to thrive) were more frequent in AGA-
positive patients and very similar to those reported in NCGS cohorts, although they could 
not distinguish NCGS patients among other AGA-positive patients. 
Three AGA-positive patients out 11 (27%), i.e. 1/6 (17%) AGA-positive NCGS patients and 
2/5 (40%) AGA-positive no-NCGS patients tested positive for TG6 IgA. None of  the 
subjects tested positive for TG6 IgA in the AGA-negative group. No one tested positive for 
TG6 IgG either. Patients with high levels of  TG6 antibodies did not show clinical 
amelioration on a 3 months - period on gluten-free diet. 
The gene expression profiling of PBMCs from NCGS patients documented up-regulation, in 
the active phase of the disease, of a high number of genes related to T- and B-lymphocyte 
activation and up-regulation of genes related to Th17 cell subset and type I Interferon 
response. 
Levels of sCTLA-4 were significantly higher in headache AGA-positive patients than in 
AGA-negative subjects (mean levels 14.46±3.74 ng/ml vs 0.53±0.67 ng/ml; p=0.001), and 
sCTLA-4 levels markedly reduced on gluten-free diet in all subjects, despite NCGS diagnosis 
was not confirmed in some of them. The difference in mean levels at recruitment and on 
GFD was statistically significant in NCGS patients (mean levels 14.46±3.74 ng/ml vs 
4.28±3.46 ng/ml; p=0.036). 
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Serum levels of sgp130 were not significantly different at recruitment in NCGS patient, as 
compared to other AGA-positive subjects or to AGA-negative headache patients, neither 
levels of this soluble mediator significantly changed on gluten-free diet. Serum levels of 
sCD25 were similar in NCGS patients, no-NCGS patients and AGA-negative subjects.   
CONCLUSIONS 
A subgroup of  children or adolescents fully satisfying criteria for primary headaches has 
Non-celiac Gluten Sensitivity.  
Experimental data from NCGS patients suggest the existence of  an activated immune 
response with a type-1 Interferon signature. High levels of  serum sCTLA-4 in AGA-positive 
patients may be a further clue for gluten sensitization and involvement of  adaptive immunity. 
The presence of  TG6 antibodies in sera may predict a poor clinical response to gluten-free 
diet upon a 3 months – period, thus justifying a dietary treatment for 6-12 months at least, as 
recommended for patients with gluten ataxia who tested positive for TG6 antibodies. 
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INTRODUCTION 
 
1. Headache in the pediatric age 
 
Headache is one of the most common health complaints in children and adolescents, 
often with a relevant burden on quality of life. Primary headaches, mainly migraine 
and tension-type headache, account for the great majority of cases in this age group. 
Nevertheless, secondary headaches should always be considered, and an accurate 
diagnostic work-up focused on early recognition of any underlying treatable causes 
should represent a primary endpoint for physicians [Bigal 2010, Ozge 2011].  
Recently, several areas of research have contributed to better understand headache 
features in childhood, although significant gaps remain in our understanding of 
pathophysiology of this condition [Hershey 2012].  
1.1 Epidemiology 
 
Applying the International Classification of  Headache Disorders second edition 
(ICHD II) criteria, Abu-Arafeh et al. [2010] found that the prevalence of  headache 
was at approximately 58% in subjects up to 20 years of  age (female to male ratio 
1.5:1) and that it increases with age, ranging from 20% in children younger than 5 
years to 75% in children aged 15 years [Bille 1962, Silanpoo 1991]. Migraines in 
childhood range 3.9% to 7%, whereas 4% to 20% of  adolescent boys and 10% to 
27% of  adolescent girls will develop migraines [Carlsson 1996]. Boys suffer from 
migraines more than girls in early childhood, but this figure reverses at puberty [Bille 
1962].  
 
1.2 Disease characterization 
 
In recent decades several definitions of pediatric migraine have been proposed, until 
the currently accepted classification system for headaches, which was published by 
the International Headache Society in 2013, the International Classification of 
Headache Disorders third edition beta version (ICHD-III beta) [[Bigal 2010, 
Headache Classification Committee 2013].   
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Primary headaches, secondary headaches, and painful cranial neuropathies are 
separately classified in ICHD-III beta. Migraine (with or without aura), and tension-
type headache belong to the primary headache group and account for the vast 
majority of primary headaches in children. Secondary headaches represent a widely 
heterogeneous group of head pains due to traumas, intracranial or extracranial 
disorders (e.g., vascular diseases, masses, infections), assumption or withdrawal of 
substances, or disorders of homeostasis. 
Requirements for correct and timely diagnoses are demographic data of patients, 
inter-ictal symptoms, and profiles of headache attacks, as well as personal and family 
history, and a complete physical examination [Hershey 2010, Karli 2006]. Moreover, 
the unique features in childhood headaches should be taken into account for disease 
characterization in this age group. 
1.2.1 Migraine 
 
Migraine attacks are often shorter in the pediatric population than in adults, lasting 
from 1 hour (in younger patients) to 48-72 hours [Slover 2015, Tarasco 2015].  
The most frequent symptoms, for children, in migraine attacks are nausea and 
vomiting, photophobia and phonophobia, as expected for adult migraineurs, but also 
dizziness and vertigo, which are more likely in children than in adults [Tarasco 2015].  
Dizziness and vertigo, as well as vomiting or abdominal pain, but also limb and body 
pain without traumatic or rheumatologic findings, occur frequently in children with 
migraine also as isolated symptoms in the inter-ictal period, and all together account 
for the so-called “migraine variants” and “migraine-associated syndromes”. 
Some of these migraine-associated syndromes (Cyclical vomiting syndrome, 
Abdominal migraine, Benign paroxysmal vertigo, Vestibular migraine, Benign 
paroxysmal torticollis), previously known as “Periodic syndromes of childhood”, 
have been defined by the ICHD-III beta [Headache Classification Committee 2013]. 
Other common episodic syndromes in pediatric migraineurs (e.g. limb pain, 
paroxysmal dizziness, motion sickness) have not been included in ICHD-III beta 
classification yet, even though currently recognized by experts in childhood 
headaches as belonging to the spectrum of migraine variants and migraine-related 
conditions [Gupta 2016].  
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Notably, younger patients may have recurrent vomiting or abdominal pain even 
before developing recurrent head pain [Carson 2011]. Since these disorders typically 
start in young childhood prior to the ability to express headache, they may be 
underdiagnosed. Indeed, many patients receive in-deep evaluation for gastrointestinal 
disorders without clinically relevant findings, or even ex-adjuvantibus treatments for 
gastritis or gastroesophageal reflux, whereas they lack information and treatment for 
their migraine variants, which would be likely to respond to specific interventions for 
migraines. 
1.2.2 Tension-type headache 
 
Tension-type headaches (TTHs) occur in approximately 10% to 15% of youth, and 
they has been reported to be equal or more common than migraine in childhood, 
although studied only in a limited degree [Seshia 2009, Matthew 2011]. TTHs are 
usually less painful than migraines, shorter in duration, bilateral, posterior in location, 
and do not meet criteria for migraines, even though they can co-occur with migraine 
headaches and lead to chronic daily headaches [Slover 2015].  
 
1.2.3 Secondary Headaches  
 
Although primary headaches are the most common headaches, “red flags” for 
underlying causes should be systematically searched: an onset in the preschool age, a 
short history of headache or an accelerated course, elements suggesting a raised 
intracranial pressure, systemic illnesses or inter-ictal symptoms, such as fever, 
weakness, or personality changes [Celle 2010, John 2014].  
In a small minority of patients, headaches are secondary to serious life-threatening 
acute or subacute disorders (e.g., subarachnoid or cerebral parenchymal hemorrhage, 
carotid or vertebral dissection, brain mass lesions) [Conicella 2008, Scagni 2008]. 
However, the most frequently secondary headaches in various studies of pediatric 
emergency setting are those related to viral infections (29–39%) or minor head 
traumas [Lewis 2000, Conicella 2008, Abend 2010]. Nevertheless, symptoms and 
signs for other systemic disorders should be considered, e.g. causes for hypoxia, 
hypercapnia, hypoglycemia, but also iron deficiency, obstructive sleep apnea 
syndrome, or autoimmune disorders such as thyroiditis or celiac disease [Abend 
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2010]. As for the latter, physicians should remind that celiac disease often occurs 
without gastrointestinal symptoms, and it seems to be 4- to 10-fold more prevalent in 
headache patients than in the healthy general population [Gabrielli 2003, Dimitrova 
2013].  
 
1.3 Long-term prognosis 
 
Prognosis of headache primarily depends on headache phenotype. If the priority for 
secondary headaches is the identification and the proper management of underlying 
disorders, the main endpoint for primary headaches should be the reduction of 
interference of headache on quality of life through developmental ages.  
It is well-established that primary headache often have their onset in childhood and 
become progressively more prevalent. It was estimated that 25% of pediatric patients 
had recurrent headaches along a 3 years-period, and that the prevalence of high-
frequency episodic headaches or chronic daily headaches was about 1.7-2% 
in children and adolescents from the general population [Arruda 2010, Dunn 2011, 
Lipton 2011].  
 
1.4 Pathophysiology of headache  
 
1.4.1 Migraine 
 
The etio-pathogenetic features of migraine have been extensively studied, but many 
aspects are still unclear. Burstein et al. [2015] provided an extensive review on etio-
pathogenesis of migraine. 
Migraine is a multifactorial condition. A family history for migraine is reported in 
60% to 88% of patients, and some susceptibility genes have been identified, dealing 
with regulation of neurotransmitter release, glial ability to reuptake glutamate from 
the synapse, and generation of action potentials, but also regulation of synaptic 
development and plasticity [Ophoff 1996, Hernandez-Latorre 2011, Tarasco 2015, 
Burstein 2015]. However, environmental factors are necessary for the onset of 
attacks. 
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Currently, the neurovascular theory is the most accredited to explain onset of pain in 
migraine attacks. According to this theory, the initial phenomenon in migraine is 
cortical spreading depression, i.e. a slowly propagating wave of 
depolarization/excitation in cortical neurons and glia, followed by 
hyperpolarization/inhibition, possibly due to mechanisms that invoke inflammatory 
molecules as a result of physiological or emotional stress [Cui 2014, Ferrari 2015]. 
The initial membrane depolarization of cells in the cortex is associated with efflux of 
potassium, influx of sodium and calcium, release of glutamate, ATP, and hydrogen 
ions, with neuronal swelling, upregulation of genes involved in inflammatory 
processing, and activation of enzymes, such as caspase-1. This event can initiate 
inflammation by releasing interleukin-1 into the cerebro-spinal fluid, which in turns 
activates nuclear factor-kB in astrocytes, and release of cyclooxygenase-2 and 
inducible nitric oxide - synthase into the subarachnoid space. The introduction of 
pro-inflammatory molecules into the meninges and a high level of hydrogen ions 
alters the molecular environment in which meningeal nociceptors exist, and activates 
pain fibers which densely innervate meninges. When activated in an altered molecular 
environment, peripheral trigemino-vascular neurons become sensitized and begin to 
respond to dura stimuli and innocuous mechanical and thermal stimulation of 
cephalic and extracephalic skin areas as if it were noxious. The stimulation of 
meningeal nociceptors leads to the activation of the trigemino-vascular pathway. This 
pathway originates in trigeminal ganglion neurons whose peripheral axons reach the 
pia, dura, and large cerebral arteries and whose central axons reach the spinal 
trigeminal nucleus and then brainstem nuclei, hypothalamic nuclei, and basal ganglia 
nuclei. These projections may be critical for the initiation of nausea, vomiting, 
yawning, lacrimation, urination, loss of appetite, fatigue, anxiety, irritability, and 
depression by the headache itself. Additional projections of spinal trigeminal nucleus 
neurons are found in the thalamic nuclei, where relay trigemino-vascular thalamic 
neurons project to the somatosensory, insular, motor, parietal association, auditory, 
visual, and olfactory cortices, which are finally altered in their functioning, providing 
an explanation for the cortically-mediated symptoms in migraine (e.g., motor 
clumsiness, difficulty focusing, amnesia, allodynia, phonophobia, photophobia, and 
osmophobia). 
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The clinical practice with migraineurs suggests that migraine brains are extremely 
sensitive to deviations from homeostasis. Therefore, it has been hypothesized that 
hypothalamic neurons regulating homeostasis might be at the origin of some of the 
migraine prodromes (e.g., fatigue, depression, irritability, food cravings), by altering 
the balance between parasympathetic and sympathetic tone in the meninges toward 
the predominance of parasympathetic tone, thus activating meningeal nociceptors.  
1.4.2 Tension-type headache 
 
Information about pathophysiology of tension-type headache is less complete, but 
some mechanisms leading to this prevalent primary headache disease have been 
clarified and extensively reviewed by Bendtsen et al. [2011]. 
The processing of pain from myofascial tissues is finely regulated. Under some 
conditions, the painful stimulus from the pericranial myofascial tissues may be more 
prolonged or more intense than normal. The underlying mechanisms may include an 
increased muscle activity or the release of various chemical mediators secondary to 
local pathological conditions. An increased muscle activity secondary to psychogenic 
stress is likely to be of relevance in this respect. The reason may be because the 
psychogenic stress condition may cause a prolonged increase of muscle tone via the 
limbic system and potentiate pain facilitation from the brainstem to the spinal dorsal 
horn.  
In predisposed individuals, the prolonged nociceptive input from the pericranial 
myofascial tissues may lead to sensitization of nociceptive second-order neurons at 
the level of the spinal dorsal/trigeminal nucleus. It is possible that low-grade tension, 
that normally does not result in pain, does so in the presence of central sensitization. 
It also has been demonstrated that emotional factors like stress and anxiety may 
contribute to the chronicization of TTH. 
 
1.4.3 Headache and the sickness behavior 
 
It is well known that animals dealing with infections and inflammation show various 
behavioral symptoms of sickness, including lethargy, anorexia and reduced social 
activities. A body of experimental data supports the hypothesis that these behavioral 
changes are not merely the result of physical debilitation due to the infection, but 
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they represent a set of coordinated responses to the presence of infection and 
inflammation [Dantzer 1998]. Similar behavioral changes occur when humans 
experience some types of pain, particularly “inescapable” pain, i.e. the pain which 
comes from the activation of C-fibers localized in the deep viscera, meninges and 
cerebral vascular tree included, and is implied in the activation and transmission of 
visceral homeostatic pain [Bonavita 2011]. Inescapable pain leads to passive coping 
strategies characterized by a disengagement from the external environment, and 
includes motor quiescence, hyporeactivity, decreased vigilance, reduced 
responsiveness to tactile or visual stimuli, sympatho-inhibition and vasodepression. 
This complex defensive reaction has been termed as sickness behavior [Hart 1988]. 
According to this observation, it seems arguable that pain may promote the complex 
and coordinated sensorial-emotive behavioral experience underlying the allostatic 
processes, i.e. all mechanisms finalized in restoring homeostasis, including 
anticipatory behavioral measures to prevent whatever impending derangement of the 
homeostatic balance, or to maintain or restore internal homeostasis of the body 
[Cortelli 2010, Bonavita 2011]. 
As other experiences of pain, headache and all multifaceted symptoms and signs 
associated to headache attacks may be read as a complex and integrated allostatic 
defensive reaction to an inescapable pain, that allows the restoration of biologic 
homeostasis through a temporary disengagement from active interaction with 
environment. The neurochemical basis of such reaction might involve the cytokines 
system, mainly TNFα, IL-1β, and IL-6, implied in hyperalgesia and allodynia as well 
as in visceral homeostasis signaling and in the so-called immune-to-brain 
communication [Maier 1998, Watkins 2000, Quan 2008, Montagna 2010, Benson 
2012].  
Even more convincingly, it is well-established that system inflammation due to 
infections or injuries is able to induce brain inflammation [Poon 2015]. Peripheral 
cytokines can communicate with the brain via the humoral routes and the neural 
routes. In respect to the humoral routes, plasma cytokines may enter the brain at the 
choroid plexus and at the circumventricular organs which lack a complete blood-
brain barrier, thus activating local macrophage-like cells to produce cytokines into the 
brain parenchyma, or acting on the brain endothelium to stimulate the secretion of 
cytokines and prostaglandins. Furthermore, there is evidence to indicate that IL-1 
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and TNF can be actively and selectively transported into the brain via saturable 
transporter mechanisms. In terms of the neural routes, systemic cytokines can take 
effect on the primary afferent nerves. For example, the vagus nerve expresses IL-1 
receptors and prostaglandin-E receptors, and its electrical firing can be triggered by 
ligand-receptor interaction, thus conveying electrical signals to the brain, where other 
cytokines are produced. 
 
2. Gluten-related disorders 
 
Gluten is the main structural protein complex of wheat; equivalent proteins are 
present in other cereals, including rye and barley. In genetically predisposed 
individuals, gluten or some protein fractions, such as gliadins and glutenins, can be 
toxic [Sapone 2012]. 
The Figure 1 summarizes the recently accepted classification of gluten-related 
disorders, based on their pathogenesis.  
 
 
 
Figure 1. Classification of gluten-related disorders. WDEIA: wheat-dependent, exercise-
induced allergy. Modified from Sapone et  al., BMC Med. 2012 Feb 7;10:13.  
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The best known human diseases related to gluten exposure, i.e. wheat allergy and 
celiac disease, are mediated by the adaptive immune system. In celiac disease (CD), 
the reaction to gluten is mediated by T-cell activation in the gastrointestinal mucosa. 
In wheat allergy the cross-linking of specific IgE by repeat sequences in gluten 
peptides triggers the release of histamine from basophils and mast cells [Tanabe 
2008].  
CD is an autoimmune disorder, as demonstrated by specific serologic autoantibodies, 
most notably serum anti-tissue transglutaminase 2 (TGA) and anti-endomysial 
antibodies (EMA). CD is responsible for enteropathy in genetically susceptible 
individuals, who carry HLA-DQ2 or HLA-DQ8 haplotypes. Genetic predisposition 
plays a key role in CD because the presence of HLA-DQ2 and/or HLA-DQ8 is 
necessary for disease development, although it is not sufficient on its own. The 
clinical spectrum of CD includes symptomatic cases with either classical intestinal 
(e.g., chronic diarrhea, weight loss) or non-classical extra-intestinal features (e.g., 
anemia, osteoporosis, neurological symptoms), and silent forms that are occasionally 
discovered because of serological screening. Complications associated with untreated 
celiac disease include osteoporosis, impaired splenic function, neurologic disorders, 
infertility or recurrent abortion, ulcerative jejuno-ileitis, and cancer. Enteropathy-
associated T-cell lymphoma and adenocarcinoma of the jejunum are rare 
complications of celiac disease [Fasano 2012]. Enteropathy in CD is characterized by 
histological changes in duodenal mucosa, including an increased number of 
intraepithelial lymphocytes (IELs) (>25 lymphocytes per 100 enterocytes), elongation 
of the crypts, partial to total villous atrophy and a decreased villous/crypt ratio. The 
etio-pathogenesis of CD has been extensively investigated. Gluten, the 
environmental trigger, crosses the intestinal epithelium through different routes, as 
gut permeability is increased in CD. Gliadin peptides bind to the chemokine receptor 
CXCR3, which is over-expressed at the apical side of enterocytes in CD patients, 
leading to an increased release of zonulin, which enables paracellular translocation of 
gliadin peptides to the lamina propria by disassembling intercellular tight junctions. 
Once gluten reaches the lamina propria, it is deamidated by tissue tranglutaminases 
(TG), so that it becomes rich in negatively charged glutamate residues with increased 
affinity for the HLA-DQ2/-DQ8 molecules. Deamidated gluten is then presented by 
antigen presenting cells to HLA-DQ-restricted gluten-reactive CD4+ T cells. Upon 
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their activation, gluten-specific CD4+ T cells produce pro-inflammatory cytokines, 
dominated by IFNγ, thus inducing a Th1 response. In addition to Th1 cells, a 
pathogenic role in CD is also played by IL-17A-producing Th17 cells. Both Th1 and 
Th17 immune responses are enhanced by IL-21 in active CD. On the other hand, 
Th2 cytokines drive the activation and clonal expansion of B cells with subsequent 
production of anti-tranglutaminase 2 antibodies (TGA), the serological hallmark of 
CD [Sapone 2012, Di Sabatino 2015].  
Dermatitis herpetiformis and gluten ataxia are autoimmune disorders too.  
Dermatitis herpetiformis (DH) is a skin manifestation of CD: EMA and TGA occur 
in the serum, and the rash is gluten-sensitive; recently, antibodies directed at 
epidermal transglutaminase (TG3) have been identified in patients with DH and this 
may be the dominant autoantigen in the disorder [Sapone 2012].  
Gluten ataxia (GA) was originally defined as an otherwise idiopathic, sporadic ataxia 
characterized by autoimmune processes resulting in damage of the cerebellum and 
positive serological markers for gluten sensitization. GA is usually of insidious onset 
with a mean age at onset of 50 years. Pediatric cases, however, have also been 
described. GA usually presents with pure cerebellar ataxia primarily affecting gait and 
lower limbs; rarely, it can present with ataxia in combination with focal myoclonus, 
palatal tremor, or opsoclonus. Specific autoantibodies in GA have not been definitely 
established: TGA are present in about 40% of patients, some patients have AGA. 
One out 3 patients has bioptic evidence of enteropathy, but less than 10% of patients 
with GA has any gastrointestinal symptoms. Recently, antibodies directed at brain 
transglutaminase (TG6) have been identified. TG6 antibodies react with Purkinje 
cells and cells within the granular layer in the cerebellum. Moreover, accumulation of 
IgA deposits in the cerebellum and brainstem were observed in post-mortem brain 
studies, most prominently within the muscular layer surrounding vessels, with 
perivascular inflammation and changes in vessel permeability. Thus, the blood-brain 
barrier function is altered, and gluten and antibodies are allowed to enter into the 
Central Nervous System [Mitoma 2015]. It has been estimated that antibodies against 
TG2 and antibodies against TG6 can be found up to 85% of patients with ataxia 
who are positive for AGA. Thus, neurologists expert in gluten-related disorders 
recommend screening of patients with progressive cerebellar ataxia using AGA, 
TGA and anti-TG6 antibodies. Subjects positive for any of these antibodies with no 
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alternative cause for their ataxia should be offered a strict GFD: stabilization of 
neurological symptoms after one year on GFD would be a strong indicator that the 
patient suffers from GA, even though response to treatment with a gluten-free diet 
depends on the duration of the ataxia prior to the diagnosis. Autoantibodies should 
disappear within 6-12 months on GFD [Sapone 2012].  
A third clinical entity, for neither which allergic, nor autoimmune mechanisms have 
been identified, has been introduced among gluten-related disorders and generically 
named Non-Celiac Gluten Sensitivity (NCGS) [Sapone 2012, Catassi 2013]. 
 
2.1 Non-Celiac Gluten Sensitivity 
 
Non-Celiac Gluten Sensitivity is a syndrome characterized by intestinal and extra-
intestinal symptoms related to the ingestion of gluten-containing food, in subjects 
that are not affected by either celiac disease or wheat allergy. The terminology “Non-
Celiac Gluten Sensitivity” is still a matter of debate, because NCGS is triggered by 
gluten-containing cereals, but the offending dietary protein has not been identified 
yet, and could include components other than gluten itself (e.g., the cereal protein 
amylase-trypsin inhibitors) [Junker 2012, Catassi 2015].  
2.1.1 Epidemiology 
 
Epidemiological data on NCGS are scant [Volta 2015]. According to data from US, 
the prevalence of NCGS was 0.6% at a primary care level, and about 6% in a tertiary 
care center for celiac disease [Sapone 2012, Di Giacomo 2013]. An Italian 
multicenter prospective survey compared the prevalence of NCGS and CD 
diagnoses in referral pediatric and adult centers for gluten-related disorders, being 
NCGS and CD diagnosed in 3.2% and 2.8%, respectively, with an estimated 
NCGS/CD ratio about 1/1 in Italy [Volta 2014].  
NCGS appears to occur more frequently in adults (mean age at onset 40 years) and 
among females (female/male ratio 5:1) [Volta 2014]. The prevalence of markers of 
gluten-related disorders or ascertained celiac disease and NCGS are reported as 4- to 
10-fold higher in headache patients, both adults and children, than in general 
population [Gabrielli 2003, Lionetti 2009, Lionetti 2010, Dimitrova 2013]. 
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2.1.2 Clinical Picture 
 
The clinical involvement in NCGS appears to be multi-systemic.  
Gastrointestinal symptoms overlap to those reported by patients with irritable bowel 
syndrome and include abdominal pain/discomfort, bloating and bowel habit changes 
(diarrhea, alternating bowel, constipation) [Catassi 2013, Volta 2014, Volta 2015]. 
Upper gastrointestinal manifestations include epigastric pain, nausea, aerophagia, 
gastroesophageal reflux disease, and aphthous stomatitis. Extra-intestinal features 
include fatigue, headache, “foggy mind”, arm/leg numbness and anxiety/depression. 
Other systemic signs are joint/muscle pain resembling fibromyalgia, skin 
rash/dermatitis, weight loss, iron-deficiency and/or folic acid anemia and, although 
rarely, allergic manifestations such as asthma and rhinitis [Volta 2014]. 
Gastrointestinal symptoms are supposed to be more frequent in young patients than 
extra-intestinal manifestations (fatigue, headache, limb pain) [Francavilla 2014].  
More than 20% of NCGS patients show symptoms of allergy, autoimmune disorders 
seem to be rare [Sapone 2012, Volta 2012, Catassi 2013, Volta BMC Med 2014]. 
Further data are needed to establish whether complications might occur, as in CD 
[Sapone 2012, Volta 2013]. 
2.1.3 Diagnostic Criteria 
 
NCGS should be suspected in patients with persistent intestinal and/or extra-
intestinal complaints which worsen after eating gluten-rich food but do not display 
the CD and wheat allergy serologic markers.  
Although the most specific CD serologic markers, such as TGA and EMA, are 
negative in NCGS patients by definition, IgG-class AGA directed against native 
gliadin are found more frequently in these cases (about 50%) than in the general 
population, when eating a gluten-containing diet. Therefore, the finding of isolated 
IgG-AGA positivity may be a clue to the diagnosis of NCGS. When initially positive, 
some authors observed that IgG AGA normalize more quickly in NCGS than CD 
patients after starting treatment with the GFD [Caio 2014]. However, the 
determination of IgG AGA cannot be recommended for clinical use due to the poor 
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specificity of this test, being found in CD (80–90% of patients), autoimmune liver 
disorders (21,5%), connective tissue disease (9%) and Irritable Bowel Syndrome 
(20%), as well as in healthy controls (2-8%) [Volta 2008, 2012 Catassi 2015]. 
Any correlation with HLA-DQ2 and/or -DQ8 has been identified [Sapone 2012, 
Volta 2012]. 
Since no biomarker is sensitive and specific enough for diagnostic purposes, the aim 
of the confirmation of the diagnosis of NCGS should include two subsequent stages 
in the patient who is on a normal, gluten-containing diet: (1) assessing the clinical 
response to the gluten-free diet; (2) measuring the effect of reintroducing gluten for 
one week followed by a one-week washout of strict GFD and by the crossover to the 
second one-week challenge, possibly in a blinded manner. The standardization of the 
diagnostic procedure has been published last year. The threshold of a 30% increment 
in symptoms in the gluten challenge stage has been proposed as a positive challenge, 
but this threshold is arbitrary and needs validation [Catassi 2015].  
Performing a duodenal biopsy on a gluten-containing diet is another important step 
in the diagnostic approach to NCGS, particularly to rule out an underlying 
seronegative CD [Volta 2015]. Although small bowel villous architecture is normal in 
NCGS, the number of intraepithelial lymphocytes (IELs), defined normal if ≤25% [], 
is increased in a high proportion of patients, thus suggesting the existence of a 
mucosal low-grade inflammation [Hayat 2002, Sapone 2011, Volta 2014]. This mild 
lymphocytic intestinal infiltration can result in a specific NCGS histological pattern, 
characterized by a linear distribution of CD3+ T lymphocytes in the deeper part of 
the mucosa, together with clusters of the same cells in the superficial epithelium 
[Villanacci 2013]. Unlike CD, in NCGS there is no increase of T-cell receptor 
gamma/delta IELs [Sapone 2011]. Although small intestinal mucosa in NCGS shows 
a normal (i.e. >3:1) villous/crypt ratio, it is acknowledged that a mild inflammation 
may contribute to impair intestinal absorption [Volta 2012]. 
The Figure 2 summarizes the clinical and diagnostic features of NCGS, compared to 
celiac disease and wheat allergy. 
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Figure 2. Clinical and diagnostic features of Non-celiac Gluten Sensitivity (NCGS), 
compared to Celiac Disease (CD) and Wheat Allergy (WA). From Catassi C. Gluten 
Sensitivity. Ann Nutr Metab 2015; 67 Suppl 2:16-26. 
 
2.1.4 Pathophysiology 
 
The etio-pathogenetic features of NCGS are still unclear [Elli 2015]. 
In a study conducted by Sapone et al. [2011], NCGS subjects did not show increased 
intestinal permeability. Coherently with this observation, authors documented that 
the claudin-1 and zonulin-1 expression in the intestinal epithelium was similar in 
NCGS, celiac patients and dyspeptic patients. Conversely, in NCGS patients a  
significantly higher expression of claudin-4, i.e. a claudin isoform postulated to 
decrease tight junction-dependent permeability in the intestinal epithelium, was 
observed [Sapone 2011]. As for the immune system activation, an increased 
expression of toll-like receptor (TLR)-2, TLR-1 and TLR-4, and a significant 
reduction of T-regulatory cell marker FoxP3 relative to controls and CD patients was 
observed, without any increase in adaptive immunity-related gut mucosal gene 
expression, including interleukin (IL)-6, IL-21 and interferon-gamma. These changes 
in NCGS led to hypothesize a primary role of the innate immune system in the 
pathogenesis of the disease, without any relevant involvement of the adaptive 
immune response [Sapone 2011].  
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By exploring the initial mucosal immunologic events in NCGS patients before and 
after a gluten challenge, Brottveit et al. [2013] observed a significant increase in 
expression of IFNγ after challenge with gluten, thus supporting a possible 
pathogenic role for adaptive immunity in this syndrome. Changes neither in density 
of CD3+ IELs, nor in expression of IL-8, TNFα, MCP-1, Hsp27, or Hsp70 were 
found in response to challenge. 
Bucci and colleagues [2013] evaluated the expression of markers of activated innate 
and adaptive immunity after stimulation with gliadin in duodenal biopsies of NCGS 
patients, but they failed to identify any increase in the expression of these markers. 
Shuppan and colleagues [2015] suggested that molecules other than gluten, i.e. wheat 
amylase-trypsin inhibitors (ATIs), might play a major role as triggers of the innate 
immune response in NCGS. ATIs are water-soluble, wheat globulins, which are 
resistant to proteolytic digestion by the gastrointestinal proteases trypsin and pepsin. 
In in vitro studies, ATIs engage the TLR4-MD2-CD14 complex, leading to an up-
regulation of dendritic cell maturation markers and to the release of pro-
inflammatory cytokines in myeloid cells. Data from healthy controls are comparable 
to those from celiac and NCGS patients, in line with innate immune activation. 
Valerii and collaborators [2015] studied how a mix of wheat proteins (gliadin, 
glutenin, lectins, wheat germ agglutinin and ATIs) activated cultured peripheral blood 
mononuclear cells from NCGS patients. Authors documented over-expression of 
CXCL10, a pro-inflammatory chemokine produced mainly by neutrophils and 
macrophages to recruit leukocytes which is able to decrease the intestinal epithelial 
barrier function in vitro.  
In a different line of research, Biesiekierski et al. [2013] indicated wheat fermentable 
oligosaccharides, disaccharides, monosaccharides and polyoils (FODMAPs) as poorly 
absorbed short-chain carbohydrates, which could be responsible for intestinal 
distension after fermentation and thus for gastrointestinal complaints, in a cohort of 
NCGS patients with predominant irritable-bowel syndrome symptoms. 
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CHAPTER I: AIMS OF THE STUDY 
 
The study design accounted for three subsequent stages. 
The first stage aimed to explore: 
- the prevalence of IgA and/or IgG native anti-gliadin antibodies (AGA) and 
IgA tissue transglutaminase-2 antibodies (TGA) in sera from children and 
adolescents evaluated for headache in a tertiary referral hospital for pediatric 
neurological diseases; 
- the prevalence of Non-celiac Gluten Sensitivity in pediatric headache patients 
with AGA; 
- the clinical picture of pediatric headache patients with NCGS. 
The second stage aimed to analyze gene expression profiles in peripheral blood 
mononuclear cells from pediatric headache patients with NCGS.  
The third stage aimed to validate some of gene array results by the measurement of 
soluble mediators in sera of AGA-positive headache patients with NCGS, compared 
to AGA-positive, no-NCGS, headache patients, or to AGA-negative headache 
patients, and to determine serum levels of TG6 antibodies, as markers of 
neurological  gluten-related disorders.  
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CHAPTER II: PATIENTS AND METHODS 
 
2.1 Stage 1: Observational, prospective cohort study exploring NCGS in pediatric 
headache patients  
 
2.1.1 Inclusion and exclusion criteria 
 
All consecutive patients aged less than 18 years and evaluated for headache at the Child 
Neuropsychiatry Unit, University Hospital of  Verona, Italy, in the period 1/03/13 – 
31/07/15 were considered for recruitment in the study.  
Inclusion criteria were the following: 1) to be diagnosed with a kind of  primary 
headaches according to the ICHD III-beta criteria; 2) to accept dosage of  total IgA, 
AGA IgG and IgA, TGA IgA, and specific IgE to wheat, gluten, gliadin on serum 
samples. 
A written informed consent was obtained from legal representatives of  all participants. 
The study was approved by the local Ethical Committee. 
Data on personal and family history of  headache, allergy, autoimmune, and 
gastrointestinal disorders were collected. Patients’ age, sex, headache phenotypes, as well 
as intestinal and extra-intestinal complaints, were registered at the recruitment. 
All patients were investigated with a complete blood count, biochemical analyses and 
evaluation of  liver, renal and thyroid function and dosage of  total IgA and TGA IgA 
(Eu-tTG® IgA kit, Eurospital, Trieste, Italy; cut-off  levels: negative <9 U/ml, 
borderline 9-16 U/ml, positive >16 U/ml).  
Patients were excluded if  one of  the following conditions occurred, at least: fulfilled 
criteria for secondary headaches or cranial nerve neuralgias; ongoing treatments for 
headache introduced or modified less than 2 months before; partial or total IgA 
deficiency, according to reference values for age; to have tested positive for TGA IgA 
(suspected diagnosis of  celiac disease) or IgE to wheat, gluten, gliadin (suspected 
diagnosis for wheat allergy); presence of  enteropathy as in celiac disease at duodenal 
biopsy. 
Determination of  AGA IgA was performed with the commercial ELISA kit α-
Gliatest® S IgA kit, Eurospital, Trieste, Italy (cut-off  levels: negative ≤8 U/ml, 
borderline 8.01-15 U/ml, positive >15 U/ml), determination of  AGA IgG with α-
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Gliatest® S IgG kit, Eurospital, Trieste, Italy (cut-off  levels: negative <50 U/ml, 
positive ≥50 U/ml). Although, according to unpublished preliminary data and taken 
into account the sensitivity and specificity of  AGA test, and of  the adopted commercial 
method in particular, we considered the cut-off  levels of  8 U/ml for AGA IgA and 25 
U/ml for AGA IgG. Based on the determination of  AGA, patients were assigned to the 
“AGA-positive” or the “AGA-negative” group.  
 
2.1.2 AGA-positive patients 
 
At the recruitment, AGA-positive patients also underwent a duodenal biopsy to exclude 
CD. Biopsy specimens were histologically evaluated according to the Marsh 
classification scheme [Marsh 1992]. Immunostaining to identify intraepithelial 
lymphocytes (IELs) was performed; intraepithelial lymphocytosis was defined as the 
presence of  >25 IELs/100 epithelial cells. Immunohistochemistry with CD3, CD4 and 
CD8 markers was performed to better evaluate the lymphocyte phenotype. If  patients 
were diagnosed with enteropathy, they would have to exit the study.  
Clinical evaluation and standardized, self-administered questionnaires dealing with 
emotional/behavioral problems of  patients (Child Behavior Checklist – CBCL) and 
disability due to headache (Migraine Disability Score - MIDAS) were obtained at every 
follow-up visit, or twice at least, i.e. at recruitment and after a 3 months - period on 
gluten-free diet (GFD). Patients and their parents were informed about the management 
of  a strict gluten-free diet (i.e., no cross contamination, no gluten traces) by a dietitian 
with expertise in celiac disease and nutritional advices in the pediatric age. 
If  clinical improvement was observed on GFD, patients have been requested to 
reintroduce gluten in their diet (i.e., an average daily intake of  gluten about 10–15 g) for 
the subsequent 3 months; then, they were newly evaluated clinically and by means of  
questionnaires (follow-up visit 1). Patients experiencing headache amelioration on GFD 
and relapsing on gluten challenge received the diagnosis of  “AGA-positive NCGS” 
headache patients.  
MIDAS questionnaires were completed by parents of  participants after instructions 
provided by child neurologists attending the visit; in order to minimize biases, physicians 
had to verify correspondence in information between questionnaires and anamnestic 
data obtained by anamnestic interviews and patients’ headache attacks diaries. MIDAS 
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questionnaires were scored as indicated by the questionnaire protocol. In order to 
evaluate amelioration, the MIDAS score at recruitment was compared to that at follow-
up visit 1; similarly, the MIDAS score at post-GFD visit was compared to the score at 
follow-up visit 2, in order to evaluate relapse. Amelioration and relapse of  symptoms 
were defined as a difference ≥50% between MIDAS total scores in 2 subsequent visits. 
Pain severity on a 0 (no pain) to 10 (maximum pain) - scale was also registered in 
MIDAS questionnaires at every follow-up visit. 
CBCL questionnaires, completed by parents of  participants as regards the last 3 
months-period after instructions provided by child neurologists attending the visit, were 
scored as indicated by the questionnaire protocol. The broad-band scores “Internalizing 
problems” and “Externalizing problems” were registered, as well as the narrow-band 
sub-score “Somatic complaints”. Scores were expressed as t-scores, in order to consent 
comparison among heterogeneous groups for age and sex. 
Whenever possible, blood samples were collected from AGA-positive patients at every 
follow-up visit. Data from patients, whose samples were collected at recruitment and 
follow-up visit 1 at least, were considered suitable for the analysis. Additionally, blood 
samples for collection of  peripheral blood mononuclear cells were obtained from 
patients diagnosed with NCGS at follow-up visit 2. 
 
2.1.3 AGA-negative patients 
 
Clinical evaluation and standardized, self-administered questionnaires dealing with 
emotional/behavioral problems of  patients (Child Behavior Checklist – CBCL) and 
disability due to headache (Migraine Disability Score - MIDAS) were obtained from 
AGA-negative patients at the recruitment and two subsequent follow-up visits, after 3 
months apart, on normal, gluten-containing diet (i.e., an average daily intake of  gluten 
about 10–15 g). 
MIDAS and CBCL questionnaires were scored as indicated by the questionnaire 
protocol, and scores managed as in AGA-positive patients. 
Whenever possible, serum samples were collected at every follow-up visit; although, 
data from patients, whose samples were collected at recruitment and follow-up visit 1 at 
least, were considered suitable for the analysis. 
Serum samples separated from blood collected from patients and controls were stored 
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frozen at -20°C until assayed. 
 
2.1.4 Statistical Analyses 
 
For continuous variables, the Wilcoxon test was used for comparison of  the mean 
values among groups. All statistical tests were 2-tailed and performed at a 5% level of  
significance. 
 
2.2 Stage 2: Analysis of  gene expression profiles in peripheral blood 
mononuclear cells from patients with headache associated to NCGS. 
 
2.2.1 Isolation of  peripheral blood mononuclear cells  
 
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized peripheral 
blood through density gradient centrifugation using Lymphoprep Ficoll-Isopaque (Axis-
Shield, Oslo, NO) according to manufacturer’s instruction. Briefly, 10mL peripheral 
blood was diluted with 10mL PBS and then layered over 10mL Lymphoprep in a 50mL 
centrifuge tube. Samples were centrifuged at 800×g for 20 minutes and cells were 
collected using a Pasteur pipette. Cells were washed twice with PBS at 1200 rpm for 10 
minutes and then counted in a Burker chamber using acridine orange staining. 
 
2.2.2 Preparation of  cRNA and array analysis 
 
Total RNA was extracted from PBMCs using TRIzol reagent (Invitrogen, Carlsbad, CA, 
USA), following manufacturer’s instructions. 
Preparation of  cRNA hybridization and scanning of  probe arrays for each sample were 
performed according to the protocols of  the manufacturer (Affymetrix, Santa Clara, 
CA, USA) by Cogentech Affymetrix microarray unit (Campus IFOM IEO, Milan, Italy) 
using the Human Genome U133A 2.0 Gene Chip (Affymetrix). The Human Genome 
U133A Gene Chip is a single array representing 14,500 well-characterized human genes 
and including more than 22,000 probe sets and 500,000 distinct oligonucleotide features. 
The different gene expression patterns were analyzed using the Gene Spring software, 
version 12.1 (Agilent Technologies, Santa Clara, CA, USA) that calculated a robust 
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multi-array average of  background-adjusted, normalized, and log-transformed intensity 
values applying the Robust Multi-Array Average algorithm (RMA). With this software 
the mean optical background level for each array was subtracted from the signal 
intensity for each probe. The normalized background-corrected data were transformed 
to the log2 scale. Signal log2 ratio of  1.0 indicates an increase in the transcript level by 
twofold change (2 F.C.) and -1.0 indicates a decrease by twofold (-2 F.C.). A signal log2 
ratio of  zero would indicate no change. The unpaired t-test was performed to determine 
which genes were modulated at a significant level (p<0.01) and p-values were corrected 
for multiple testing by using Bonferroni correction. Finally, statistically significant genes 
were selected for final consideration when their expression was at least 1.5-fold different 
in the test sample versus control sample. Genes that passed both the p-value and the FC 
restriction were submitted to a functional classification according to the Gene Ontology 
(GO) annotations (http://www.geneontology.org/). 
 
2.3 Stage 3: Detection of  soluble mediators and Transglutaminase-6 antibodies 
in serum samples from patients with headache associated to NCGS 
 
The analysis of  gene expression profiles was paralleled by the detection of  some soluble 
mediators in serum samples of  patients, by means of  commercially available ELISA kits. 
We decided to analyze levels of  soluble CTLA-4 (sCTLA-4) and soluble gp130 (sgp130) 
in serum samples collected at recruitment and after the 3 months - period on gluten-free 
diet, from AGA-positive NCGS headache patients. Findings in these patients were 
compared to those from AGA-positive, no-NCGS, headache patients, and from AGA-
negative headache patients. Commercial ELISA kits were used for the determination of  
serum levels of  sCTLA-4 (sCD152/CTLA-4 Human ELISA®, BioVendor Laboratory 
Medicine, Inc., Bratislava, Slovakia) and sgp130 (Quantikinine ELISA Human soluble 
gp130®, R&D Systems, Minneapolis, USA).  
Additionally, we decided to analyze levels of  soluble IL-2 receptor alfa (sCD25), a well-
established biomarker of  activated peripheral blood T-lymphocytes. The commercially 
available ELISA kit purchased from Novus Biologicals (Littleton CO, USA) was used 
according to the manufacturer’s instructions. 
Further, being TG6 antibodies described as serological markers of  gluten-related 
disorders with a major neurological involvement, the determination of  IgA and IgG 
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Tranglutaminase-6 antibodies was performed in sera of  headache patients. The 
commercial ELISA kits from Zedira, Ebringen, Germany (cut-off  levels for Tg6 IgA: 
negative <26 U/ml, borderline 26-41 U/ml, positive >41 U/ml; cut-off  levels for Tg6 
IgG: negative <28 U/ml, borderline 28-44 U/ml, positive >44 U/ml) were used. 
Figures 3-5 show calibration curves obtained for ELISA assays and applied to calculate 
analyte concentrations in serum samples. 
 
 
 
 
 
 
 
 
Figure 3. Calibration curves for TG6 IgA ELISA assay and TG6 IgG ELISA assay. 
 
 
 
 
 
 
 
 
Figure 4. Calibration curves for sgp130 ELISA assay and sCTLA-4 ELISA assay. 
 
 
 
 
 
 
 
 
Figure 5. The calibration curve for sCD25 ELISA assay. 
 
   TG6 IgA level [I.U./ml] 
[I.U./ml] 
TG6 IgG level [I.U./ml] 
 
gp130 ELISA prova
10-02-2016
sgp130 [ng/ml]
0,1 1 10 100
O
p
tic
a
l D
e
n
sity
0,0
0,5
1,0
1,5
2,0
sCTLA-4 concentration [ng/ml]
0,1 1 10 100
O
p
ti
c
a
l 
D
e
n
si
ty
0,0
0,5
1,0
1,5
2,0
2,5
3,0
 sCD25/IL-2 R alpha  [ng/ml]
0,1 1 10 100
O
p
tic
a
l D
e
n
sity
0,0
0,5
1,0
1,5
2,0
2,5
  
33 
 
CHAPTER III: RESULTS 
 
3.1 Stage 1: Observational, prospective cohort study exploring NCGS in pediatric 
headache patients 
 
Among 60 patients aged less than 18 years with primary headache examined for 
eligibility, 40 subjects accepted serologic examination for gluten-related disorders. None 
of  the subjects tested positive for TGA IgA, IgE to wheat, gluten, gliadin, or AGA IgA; 
no one had IgA deficiency. Twenty patients (50%) tested positive for AGA IgG. 
Consequently, all were confirmed eligible for the study. 
Seventeen patients out 40 who had serologic tests (43%) accepted to enter the study: 11 
subjects (4 males, 7 females; mean age, 10.6 years; age range, 7.9-12.5 years) belonged to 
the AGA-positive group, 6 children (2 males, 4 females; mean age, 11.6 years; age range, 
9.1-13.8 years) to the AGA-negative group. Thus, 55% of  patients who tested positive 
for AGA and 30% of  patients who tested negative for AGA participated in the study. 
 
3.1.1 Headache clinical course during the diagnostic phase 
 
AGA-positive patients underwent the 3 months – period on GFD and then the gluten 
challenge was performed for patients who experienced clinical amelioration. Thus, 6 out 
11 AGA-positive patients (55%) received the diagnosis of  NCGS, confirmed by clinical 
improvement on GFD and relapse on gluten challenge. NCGS was not confirmed in 5 
AGA-positive patients due to lack of  clinical benefit on GFD (one case), or lack of  
symptom relapse with the gluten challenge (4 patients). The flow-chart in Figure 6 
shows the study design. 
Figures 7-9 and Tables 1-2 summarize data from MIDAS questionnaires, completed at 
recruitment and within the follow-up period, in AGA-positive and AGA-negative 
patients; AGA-positive patients were further stratified, on the basis of  their response to 
GFD and gluten challenge.  
Tables 3-5 summarize data from CBCL questionnaires, completed at recruitment and 
within the follow-up period, in AGA-positive and AGA-negative patients. Headache 
appeared to have a similar burden on AGA-positive and AGA-negative patients at 
recruitment. However, a subgroup of  AGA-positive patients experienced clinical benefit 
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on GFD and relapse on gluten challenge, and consensually CBCL “Internalizing 
problem” score and “Somatic complaints” score decreased at the first follow-up visit 
and returned at the recruitment level after challenge. In other AGA-positive patients, 
and in AGA-negative subjects, CBCL scores were nearly unchanged within the follow-
up period. 
 
 
 
 
 
Figure 6. The study design. 
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Figure 7. MIDAS Total score at recruitment and within the follow-up period in AGA-positive, 
NCGS patients. Patients displayed clinical improvement on GFD (follow-up visit 1) and 
relapse on gluten challenge (follow-up visit 2). 
 
 
Figure 8. MIDAS Total score at recruitment and within the follow-up period in AGA-positive, 
no-NCGS patients. Patients were on GFD at F.U. visit 1 and on gluten-containing diet on F.U. 
visit 2. A patient lacked clinical benefit on GFD, 4 patients lacked symptom relapse with the 
gluten challenge (follow-up visit 2).   
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Figure 9. MIDAS Total score at recruitment and within the follow-up period in AGA-negative 
patients. Patients were on normal, gluten-containing diet within the follow-up period. 
 
 
Table 1. MIDAS scores in AGA-positive and AGA-negative patients, at the recruitment and 
within the follow-up period. 
 
 
MIDAS score 
recruitment 
(mean ± SD) 
MIDAS score 
F.U. visit 1 
(mean ± SD) 
MIDAS score 
F.U. visit 2 
 (mean ± SD) 
AGA-positive pts (all) 37 ± 25 20 ± 27 25 ± 18 
AGA-positive NCGS 30 ± 20 9 ± 8 29 ± 17 
AGA-positive no-NCGS 46 ± 31 34 ± 36 18 ± 20 
AGA-negative pts 10 ± 7 4 ± 4 1 ± 2 
 
Table 2. Pain intensity scores on a 0-to-10 scale in AGA-positive and AGA-negative patients, at 
the recruitment and within the follow-up period. 
 
 
Pain intensity 
recruitment 
(mean ± SD) 
Pain intensity 
F.U. visit 1 
(mean ± SD) 
Pain intensity 
F.U. visit 2 
 (mean ± SD) 
AGA-positive pts (all) 8 ± 2  6 ± 3 7 ± 2 
AGA-positive NCGS 8 ± 2  6 ± 2  8 ± 2  
AGA-positive no-NCGS 7 ± 1  6 ± 3  6 ± 1  
AGA-negative pts 8 ± 1 6 ± 1 4 ± 3 
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Table 3. CBCL “Internalizing problems” (INT) t-scores in AGA-positive and AGA-negative 
patients, at the recruitment and within the follow-up period. A t-score ≥67 corresponds to a 
clinically significant condition. 
 
 
INT t-score 
recruitment 
(mean ± SD) 
INT t-score 
F.U. visit 1 
 (mean ± SD) 
INT t-score 
F.U. visit 2 
 (mean ± SD) 
AGA-positive pts (all) 56 ± 7  52 ± 6 53 ± 5 
AGA-positive NCGS 59 ± 7  52 ± 5   55 ± 5   
AGA-positive no-NCGS 51 ± 5   52 ± 7   52 ± 6   
AGA-negative pts 60 ± 6 62 ± 8 56 ± 5 
 
 
Table 4. CBCL “Somatic complaints” (SC) subscale t-scores in AGA-positive and AGA-
negative patients, at the recruitment and within the follow-up (F.U.) period. A t-score ≥67 
corresponds to a clinically significant condition. 
 
 
SC t-score 
recruitment 
(mean ± SD) 
SC t-score 
F.U. visit 1 
(mean ± SD) 
SC t-score 
F.U. visit 2 
 (mean ± SD) 
All AGA-positive pts (all) 65 ± 7 58 ± 7 64 ± 8 
AGA-positive NCGS 69 ± 6   56 ± 7   68 ± 7   
AGA-positive no-NCGS 60 ± 5   61 ± 8   58 ± 7  
AGA-negative pts 62 ± 7 61 ± 7 59 ± 12 
 
 
Table 5. CBCL “Externalizing problems” (EXT) t-scores in AGA-positive and AGA-negative 
patients, at the recruitment and within the follow-up (F.U.) period. A t-score ≥67 corresponds to 
a clinically significant condition. 
 
 
EXT t-score 
recruitment 
(mean ± SD) 
EXT t-score 
F.U. visit 1 
 (mean ± SD) 
EXT t-score 
F.U. visit 2 
 (mean ± SD) 
AGA-positive pts (all) 46 ± 6  46 ± 7 43 ± 8 
AGA-positive NCGS 46 ± 5   44 ± 7    43 ± 7    
AGA-positive no-NCGS 45 ± 8    47 ± 7    43 ± 11   
AGA-negative pts 53 ± 5 51 ± 15 45 ± 9 
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3.1.2 Headache phenotype and migraine-related conditions 
 
Primary headache phenotypes (migraine, or migraine associated to tension-type 
headache, and tension-type headache) were similarly distributed among AGA-positive 
NCGS patients, AGA-positive no-NCGS patients, and AGA-negative patients (Table 6). 
Syndromes belonging to the spectrum of  migraine variants and migraine-related 
conditions (i.e., abdominal migraine, acetonemic crises, cyclic vomiting, paroxysmal 
vertigo, paroxysmal torticollis, motion sickness, limb pain) occurred more frequently in 
AGA-positive patients, even though they were similarly distributed among AGA-positive 
NCGS patients, and AGA-positive no-NCGS patients (Table 6). 
 
Table 6. Headache phenotypes in AGA-positive and AGA-negative patients.  
 
 
AGA-positive pts 
AGA-negative 
pts 
 
NCGS no-NCGS All All 
 
N. pts (%) N. pts (%) N. pts (%) N. pts (%) 
Migraine or migraine+TTH * 5/6 (83%) 5/5 (100%) 10/11 (91%) 5/6 (83%) 
Pure TTH * 1/6 (17%) 0/5 (0%) 1/11 (9%) 1/6 (17%) 
Migraine-associated syndromes 6/6 (100%) 5/5 (100%) 11/11 (100%) 4/6 (67%) 
 
* TTH: tension-type headache. 
 
3.1.3 Gastrointestinal and extra-intestinal complaints 
 
Gastrointestinal symptoms (i.e., bloating, diarrhea) occurred more frequently in AGA-
positive NCGS patients than in other groups (Table 7). 
Extra-intestinal symptoms (fatigue, depression, anemia, long-lasting low-grade fever, 
dermatitis, failure to thrive) were similarly distributed in AGA-positive NCGS patients 
and AGA-positive no-NCGS patients, although they occurred more frequently in AGA-
positive patients than in AGA-negative subjects (Table 7). 
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Table 7. Clinical features other than headache in AGA-positive and AGA-negative patients. 
 
 
AGA-positive pts 
AGA-negative 
pts 
 
NCGS no-NCGS All All 
 
N. pts (%) N. pts (%) N. pts (%) N. pts (%) 
Gastrointestinal symptoms 3/6 (50%) 1/5 (20%) 4/11 (36%) 1/6 (17%) 
Extra-intestinal symptoms 6/6 (100%) 4/5 (80%) 10/11 (91%) 2/6 (33%) 
 
 
3.1.4 Associated disorders 
 
Symptoms of  inhalant and food allergy were similarly distributed in AGA-positive 
NCGS patients, and AGA-positive no-NCGS patients. Although, they occurred more 
frequently in AGA-positive patients than in AGA-negative subjects (Table 8). 
None of  the subjects had autoimmune disorders; oral lichen planus occurred in one 
case in the AGA-positive, no-NCGS group (Table 8). 
 
Table 8. Comorbidities in AGA-positive and AGA-negative patients. 
 
 
AGA-positive pts AGA-negative pts 
 
NCGS no-NCGS All All 
 
N. pts (%) N. pts (%) N. pts (%) N. pts (%) 
Allergy 2/6 (33%) 2/5 (40%) 4/11 (36%) 0/6 (0%) 
Other immune-mediated diseases  0/6 (0%) 1/5 (20%) 1/11 (9%) 0/6 (0%) 
 
 
3.1.5 Family antecedents 
 
As shown in Table 9, family antecedents for primary headaches were similarly 
distributed in AGA-positive NCGS patients, AGA-positive no-NCGS patients, and 
AGA-negative patients.  
A family history of  allergy occurred similarly in AGA-positive NCGS patients, and 
AGA-positive no-NCGS patients. Although, it was more frequent in AGA-positive 
patients than in AGA-negative subjects.  
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A family history of  autoimmune diseases was more frequent in AGA-positive no-NCGS 
patients than in other groups, whereas it was similarly distributed in AGA-positive 
NCGS patients, and AGA-negative patients. 
 
Table 9. Family antecedents in AGA-positive and AGA-negative patients. 
 
 
AGA-positive pts AGA-negative pts 
 
NCGS no-NCGS All All 
 
N. pts (%) N. pts (%) N. pts (%) N. pts (%) 
Headache 6/6 (100%) 5/5 (100%) 11/11 (100%) 5/6 (83%) 
Allergy 4/6 (66%) 4/5 (80%) 8/11 (73%) 2/6 (33%) 
Autoimmune diseases 3/6 (50%) 4/5 (80%) 7/11 (64%) 3/6 (50%) 
 
 
3.1.6 Duodenal biopsy 
 
All AGA-positive patients had duodenal biopsy on gluten-containing diet. 
None of  the subjects displayed histological signs of  enteropathy or an increased number 
of  IELs in duodenal mucosa, as confirmed by immunohistochemistry. In a single 
patient the mucosal eosinophilic count appeared to be mildly increased, without any 
other pathological findings. 
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3.2 Stage 2: Analysis of  gene expression profiles in peripheral blood 
mononuclear cells from patients with headache associated to NCGS  
 
In order to identify specific gene signatures possibly associated to NCGS, we compared 
gene expression profiles of  peripheral blood mononuclear cells obtained from NCGS 
patients with samples obtained from 5 healthy, age- and sex-matched donors. We 
observed that 1585 modulated genes complied with the Bonferroni–corrected p-value 
criterion and the fold change criterion, showing robust and statistically significant 
variation between healthy controls and NCGS samples. In particular, 860 transcripts 
resulted to be up-regulated and 725 transcripts were down-regulated. According to the 
Gene Ontology analysis, modulated genes were then classified in different functional 
classes, including immune response, inflammation, signal transduction, apoptosis and 
cell proliferation (Figures 10-11). Interestingly, 80 modulated genes belong to the 
functional category “Immune Response”. Therefore, in the attempt to dissect the role 
of  immune system in this clinical syndrome, we focused our attention on genes related 
to immune system functions. Modulated genes were classified on the basis of  the role 
played in the immune response and listed in Tables 10A-C, which also includes 
GeneBank accession numbers and fold changes.  
We observed that genes involved in the innate immune response, as well as those related 
to the adaptive immune response, were represented. Twenty genes prevalently involved 
in T-cell activation (e.g., CD28, CD3E, CD3G, CTLA-4, IL24, IL32, TNFRSF25) were 
up-regulated. Interestingly, 9 Th17 lymphocyte-related genes (e.g. IL4R, IL2RG, gp130, 
IL1B, IL7R, STAT6, STAT5B, SOCS3 and CXCL2) were up-regulated. Thirty-eight 
transcripts prevalently involved in B-cell activity (e.g., gp130, CLEC2D, IL2RG, IL6R, 
KLF12 and CD27) were modulated, thus suggesting a concomitant activation of  this 
cell subset. Also 14 genes involved in NK activity were modulated: CLEC2D was up-
regulated, whereas LILRA1, LILRA2, LILRA2, LILRA5, LILRB2 and LILRB4 were 
down-regulated. Finally, 6 type I Interferon inducible genes were up-regulated (IFNA17, 
IRF3, IRF5, STAT2, STAT1, LY9), thus indicating a type I IFN signature. Moreover, we 
noticed that a number of  genes related to macrophage activation (e.g. MARCO) were 
down-regulated. 
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Figure 10. A. Scatter plot of  normalized relative signal intensity (log10) of  genes satisfying the 
p-value cut-off  (p<0.01). B. Scatter plot of  normalized relative signal intensity (log10) of  genes 
differently expressed with 1.5-fold change. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  Distribution of  genes which were modulated in the analysis of  gene expression 
profiles in peripheral blood mononuclear cells from AGA-positive NCGS patients. 
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Table 10A. The most relevant genes related to innate and adaptive immune response and differently expressed. 
 
Public ID Gene Title Symbol FC 
T cell activation    
NM_001626 v-akt murine thymoma viral oncogene homolog 2 AKT2 2,36 
AF222343 CD28 molecule CD28 2,75 
NM_000733 CD3e molecule, epsilon (CD3-TCR complex) CD3E 2,67 
NM_000073 CD3g molecule, gamma (CD3-TCR complex) CD3G 2,13 
NM_001190720 inhibitor of K light polypeptide gene enhancer in B-cells, kinase beta IKBKB 2,69 
NM_002228.3 jun proto-oncogene JUN 3,07 
U07236 lymphocyte-specific protein tyrosine kinase LCK 2,05 
NM_030662 mitogen-activated protein kinase kinase 2 MAP2K2 1,83 
NM_005921 mitogen-activated protein kinase kinase kinase 1 MAP3K1 1,52 
NM_001278548 mitogen-activated protein kinase 8 MAPK8 2,33 
U57843 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta PIK3CD 1,88 
NM_181523 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) PIK3R1 2,76 
NM_002660 phospholipase C, gamma 1 PLCG1 1,53 
NM_006908 rho family, small GTP binding protein Rac1 RAC1 -1,92 
NM_002872 rho family, small GTP binding protein Rac2 RAC2 2,31 
NM_006939 son of sevenless homolog 2  SOS2 1,90 
NM_148965 tumor necrosis factor receptor superfamily, member 25 TNFRSF25 2,40 
NM_005214 cytotoxic T-lymphocyte-associated protein 4 CTLA4 2,26 
NM_006850 interleukin 24 IL24 2,84 
NM_004221 interleukin 32 IL32 2,10 
TH17 related genes   
NM_000418 interleukin 4 receptor IL4R 1,50 
NM_000206 interleukin 2 receptor, gamma IL2RG 1,84 
NM_002184 interleukin 6 signal transducer (gp130, oncostatin M receptor) IL6ST 4,52 
NM_000576 interleukin 1, beta IL1B 1,52 
NM_002185 interleukin 7 receptor IL7R 1,55 
AH006951 signal transducer and activator of transcription 6 STAT6 1,54 
NM_012448 signal transducer and activator of transcription 5B STAT5B 1,60 
NM_003955 suppressor of cytokine signaling 3 SOCS3 1,83 
M57731 chemokine (C-X-C motif) ligand 2 CXCL2 1,53 
Type I interferon signaling   
NM_021268 interferon, alpha 17 IFNA17 1,59 
NM_032643 interferon regulatory factor 5 IRF5 1,52 
NM_001571 interferon regulatory factor 3 IRF3 1,67 
S81491 signal transducer and activator of transcription 2, 113kDa STAT2 1,59 
NM_007315 signal transducer and activator of transcription 1, 91kDa STAT1 2,73 
NM_002348 lymphocyte antigen 9 LY9 2,05 
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Table 10B. Continues. 
 
Public ID  Gene Title Symbol FC 
B cell mediated immune response   
NM_001190720 inhibitor of k light polypeptide gene enhancer in Bcells, kinase beta IKBKB 2,69 
NM_002228.3 jun proto-oncogene JUN 3,07 
AI356412 v-yes-1 Yamaguchi sarcoma viral related oncogene homolog LYN -2,22 
NM_030662 mitogen-activated protein kinase kinase 2 MAP2K2 1,83 
NM_001278548 mitogen-activated protein kinase 8 MAPK8 2,33 
U57843 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta PIK3CD 1,88 
NM_001243975 protein phosphatase 3, catalytic subunit, gamma isozyme PPP3CC 2,00 
NM_006908 rho family, small GTP binding protein Rac1 RAC1 -1,92 
NM_002872 rho family, small GTP binding protein Rac2 RAC2 2,31 
NM_006939 son of sevenless homolog 2  SOS2 1,90 
NM_003177 spleen tyrosine kinase SYK -1,92 
NM_016543 sialic acid binding Ig-like lectin 7 SIGLEC7 -2,21 
NM_001242 CD27 molecule CD27 1,96 
NM_005238 v-ets erythroblastosis virus E26 oncogene homolog 1 ETS1 2,25 
NM_005239 v-ets erythroblastosis virus E26 oncogene homolog 2  ETS2 -1,83 
KJ896761 E74-like factor 1 (ets domain transcription factor) ELF1 1,94 
AF327066 Friend leukemia virus integration 1 FLI1 2,28 
NM_002348 lymphocyte antigen 9 LY9 2,08 
U96845 killer cell lectin-like receptor subfamily C, member 4 KLRC4 2,23 
NM_000206 interleukin 2 receptor, gamma IL2RG 1,84 
S72848 interleukin 6 receptor IL6R 1,79 
NM_002184 interleukin 6 signal transducer (gp130, oncostatin M receptor) IL6ST 4,52 
AH010423 Kruppel-like factor 12 KLF12 1,83 
NM_015995 Kruppel-like factor 13 KLF13 1,89 
NM_001767 CD2 molecule CD2 2,00 
NM_020125 SLAM family member 8 SLAMF8 -2,27 
NM_003842 tumor necrosis factor receptor superfamily, member 10b TNFRSF10B 1,50 
NM_001066 tumor necrosis factor receptor superfamily, member 1B TNFRSF1B -2,06 
NM_148965 tumor necrosis factor receptor superfamily, member 25 TNFRSF25 2,40 
NM_014452 tumor necrosis factor receptor superfamily, member 21 TNFRSF21 -1,68 
NM_003037 signaling lymphocytic activation molecule family member 1 SLAMF1 1,65 
D86359 sialic acid binding Ig-like lectin 6 SIGLEC6 1,58 
AF054818 CD84 molecule CD84 2,55 
NM_013269 C-type lectin domain family 2, member D CLEC2D 3,18 
AY532110 interleukin 11 receptor, alpha IL11RA 1,56 
AF000672 ELK1, member of ETS oncogene family ELK1 1,60 
U50748 leptin receptor LEPR -2,10 
NM_002342 lymphotoxin beta receptor (TNFR superfamily, member 3) LTBR -1,92 
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Table 10C. Continues. 
Public ID  Gene Title Symbol FC 
Response to gamma interferon   
NM_001767 CD2 molecule CD2 2,00 
NM_032643 interferon regulatory factor 5 IRF5 1,52 
NM_020125 SLAM family member 8 SLAMF8 -2,27 
AF054818 CD84 molecule CD84 2,55 
NM_002053 guanylate binding protein 1, interferon-inducible GBP1 -1,77 
NM_001571 interferon regulatory factor 3 IRF3 1,67 
NM_016107 zinc finger RNA binding protein ZFR 2,19 
NM_003037 signaling lymphocytic activation molecule family member 1 SLAMF1 1,65 
NM_002348 lymphocyte antigen 9 LY9 2,08 
NK cell activation   
NM_013269 C-type lectin domain family 2, member D CLEC2D 3,18 
NM_000418 interleukin 4 receptor IL4R 1,50 
NM_001278426 leukocyte immunoglobulin-like receptor, subfamily B, member 4 LILRB4 -1,83 
NM_024318 leukocyte immunoglobulin-like receptor, subfamily A, member 6 LILRA6 -1,74 
NM_021268 interferon, alpha 17 IFNA17 1,59 
NM_001278319 leukocyte immunoglobulin-like receptor, subfamily A, member 1 LILRA1 -2,81 
NM_006866 leukocyte immunoglobulin-like receptor, subfamily A, member 2 LILRA2 -2,35 
U96845 killer cell lectin-like receptor subfamily C, member 4 KLRC4 2,23 
NM_006865 leukocyte immunoglobulin-like receptor, subfamily A, member 3 LILRA3 -2,96 
NM_012276 leukocyte immunoglobulin-like receptor, subfamily A, member 4 LILRA4 -1,83 
NM_181985 leukocyte immunoglobulin-like receptor, subfamily A, member 5 LILRA5 -3,15 
AF004231 leukocyte immunoglobulin-like receptor, subfamily B, member 2 LILRB2 -3,41 
M37780 platelet/endothelial cell adhesion molecule 1 PECAM1 -1,73 
NM_004221 interleukin 32 IL32 2,10 
Macrophage activation   
NM_003842 tumor necrosis factor receptor superfamily, member 10b TNFRSF10B 1,50 
NM_005202 collagen, type VIII, alpha 2 COL8A2 -1,62 
NM_006770 macrophage receptor with collagenous structure MARCO -3,01 
NM_006725 CD6 molecule CD6 3,67 
NM_003177 spleen tyrosine kinase SYK -1,92 
NM_001066 tumor necrosis factor receptor superfamily, member 1B TNFRSF1B -2,06 
NM_002438 mannose receptor, C type 1 MRC1 -2,04 
NM_002053 guanylate binding protein 1, interferon-inducible GBP1 -1,77 
M37780 platelet/endothelial cell adhesion molecule 1 PECAM1 -1,73 
Complement activation   
NM_001735 complement component 5 C5 -1,60 
NM_000573 complement component (3b/4b) receptor 1 (Knops blood group) CR1 -1,79 
Antigen processing and presentation   
NM_002939 ribonuclease/angiogenin inhibitor 1 RNH1 -1,53 
NM_000544 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) TAP2 1,86 
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3.3 Stage 3: Detection of  soluble mediators and Tranglutaminase-6 antibodies in 
serum samples from patients with headache associated to NCGS  
 
The analysis of gene expression profiles was complemented by detection of some 
corresponding soluble mediators in sera of patients.  
We decided to analyze levels of soluble CTLA-4 (sCTLA-4) and soluble gp130 (sgp130) 
due to relevant changes in their transcript levels in the analysis of gene profiles, and 
literature data suggesting a role of these molecules in celiac disease and other 
autoimmune disorders. Soluble forms of the gp130 receptor protein, which are mainly 
generated by alternatively splicing of the gp130 mRNA, have been identified as able to 
selectively block IL-6 trans-signaling, thus protecting hosts from unwanted stimulation 
via IL-6 trans-signaling, i.e. the pro-inflammatory signaling pathway mediated by IL-6 
[Rose-John 2015]. Soluble forms of CTLA-4 derive from CTLA-4, a type I glycoprotein 
on the surface of activated T-cells, whose function is to attenuate the ongoing immune 
response [Brunet 1987, Linsley 1991A, Linsley 1991B]. 
The determination of sCD25 concentration and TG6 IgA and IgG levels were also 
performed at this stage.  
Figures 12-13 represent the concentration of sCTLA-4 and sgp130 in sera collected at 
recruitment and the first follow-up visit from AGA-positive NCGS patients, as 
compared to those of AGA-positive, no-NCGS patients and AGA-negative patients. All 
patients were on normal, gluten-containing diet at recruitment; at follow-up visit 1, all 
AGA-positive patients have been on gluten-free diet for 3 months, AGA-negative 
patients on normal, gluten-containing diet. 
Soluble CTLA-4 levels at recruitment on gluten-containing diet were significantly higher 
in AGA-positive patients, as compared to AGA-negative subjects (mean 14.46±3.74 
ng/ml vs mean 0.53±0.67 ng/ml, p=0.001; AGA-positive NCGS - mean 14.90±3.97 
ng/ml vs AGA-negative subjects - mean 0.53±0.67 ng/ml, p=0.005; AGA-positive no-
NCGS - mean 13.93±3.82 ng/ml vs AGA-negative subjects - mean 0.53±0.67 ng/ml, 
p=0.008), and they were similar among AGA-positive NCGS and no-NCGS patients. 
Soluble CTLA-4 levels decreased on GFD, both in AGA-positive NCGS patients (mean 
4.28±3.46 ng/ml; p=0.036) and in no-NCGS subjects (mean 2.84±1.96 ng/ml; 
p=0.059), although remaining significantly higher in AGA-positive NCGS, as compared 
to AGA-negative patients (mean 0.46±0.57 ng/ml; p=0,013). Levels of sCTLA-4 in 
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AGA-positive no-NCGS were higher than in AGA-negative patients, without reaching a 
statistical significance (mean 0.46±0.57 ng/ml; p=0,055). 
 
 
 
 
Figure 12. Soluble CTLA-4 levels at recruitment and at the first follow-up visit. All 
patients were on normal, gluten-containing diet at recruitment. At follow-up visit 1, all 
AGA-positive patients have been on gluten-free diet for 3 months, AGA-negative 
patients on normal, gluten-containing diet. Legend: (*) p<0.05; (**) p<0.01. 
 
 
Levels of  soluble gp130 were similar at recruitment in AGA-positive NCGS patients, 
AGA-positive no-NCGS patients and AGA-negative patients (mean concentration 
316.83±37.85, 306.00±20.78, 312.80±39.92, respectively). Moreover, mean sgp130 
concentrations were not modified significantly on GFD, neither in AGA-positive NCGS 
patients (316.83±37.85 vs 307.50±23.89), nor in AGA-positive no-NCGS patients 
(306.00±20.78 vs 318.25±66.78); similarly, after the gluten challenge only a slight change 
in sgp130 concentration, both in AGA-positive NCGS patients (307.50±23.89 vs 
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316.83±45.89), and in AGA-positive no-NCGS patients (318.25±66.78 vs 
337.33±57.83) was observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Soluble gp130 levels at recruitment and within the follow-up period. All 
patients were on normal, gluten-containing diet at recruitment. At follow-up visit 1, 
AGA-positive patients were on gluten-free diet, AGA-negative patients on normal, 
gluten-containing diet. At follow-up visit 2, AGA-positive patients were on gluten-
containing diet (gluten challenge). 
 
The determination of  sCD25 concentration was performed for samples collected at 
recruitment and first follow-up visit (Figure 14). Soluble CD25 concentrations were 
similar at recruitment among AGA-positive NCGS patients, AGA-positive no-NCGS 
patients and AGA-negative patients (mean concentration 5.12±2.67, 3.81±1.16, 
4.01±0.12, respectively). Levels of  sCD25 were slightly reduced on GFD both in AGA-
positive NCGS patients (5.12±2.67 vs 4.34±2.18) and in AGA-positive no-NCGS 
patients (3.81±1.16 vs 3.27±0.51), even though differences in mean concentrations was 
not statistically significant. Soluble CD25 concentrations on samples collected on GFD 
were similar both in AGA-positive NCGS patients and AGA-positive no-NCGS 
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patients to those in samples of  AGA-negative patients (mean sCD25 concentration 
4.06±1.98), who were on gluten-containing diet at the follow-up visit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Soluble CD25 levels at recruitment and at follow-up visit. All patients were 
on normal, gluten-containing diet at recruitment. At follow-up visit 1, AGA-positive 
patients were on gluten-free diet, AGA-negative patients on gluten-containing diet. 
 
As for the determination of  TG6 IgA antibodies (Figure 15), differences in mean TG6 
IgA levels among 3 patient groups were not statistically significant, neither at 
recruitment (mean concentration 11.10±15.92 I.U./ml, 49.46±71.87 I.U./ml, 4.17±3.67 
I.U./ml, in AGA-positive NCGS patients, AGA-positive no-NCGS and AGA-negative 
patients, respectively), nor within the follow-up period (mean concentration at the first 
follow-up visit: 9.84±18.29 I.U./ml, 40.43±51.21 I.U./ml, 7.92±9.88 I.U./ml; mean 
concentration at the second follow-up visit: 14.58±12.68 I.U./ml, 40.18±61.00 I.U./ml, 
11.73±3.77 I.U./ml). 
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Figure 15. TG6 IgA levels at recruitment and within the follow-up period. All patients 
were on normal, gluten-containing diet at recruitment. At follow-up visit 1, AGA-
positive patients were on gluten-free diet, AGA-negative patients on gluten-containing 
diet. At follow-up visit 2, all AGA-positive patients were on gluten-containing diet 
(gluten challenge), whereas AGA-negative patients continued on gluten-containing diet. 
 
According to the reference values indicated by the manufacturers of  the commercial 
ELISA test, none of  the subjects among AGA-negative patients was positive for TG6 
IgA, neither at recruitment, nor within the follow-up (Table 11, p. 52). Three AGA-
positive patients out 11 (27%) tested positive for TG6 IgA (Table 11). In particular, one 
out 6 (17%) AGA-positive NCGS patients and 2 out 5 (40%) AGA-positive no-NCGS 
patients had positivity to TG6 IgA. The antibody level was 43.36 I.U./ml in the AGA-
positive NCGS patient, 166 I.U./ml and 72.6 I.U./ml in the AGA-positive no-NCGS 
patients, respectively. Levels of  TG6 IgA resulted to be nearly unchanged in the AGA-
positive NCGS patient (43.36 vs 42.4 U/ml – 2% reduction) after 3 months on GFD, or 
mildly reduced in AGA-positive no-NCGS patients (166 vs 120 I.U./ml – 28% 
reduction; 72.6 vs 64 I.U./ml – 12% reduction). At follow-up visit 2 (i.e., on gluten-
containing diet for 3 months), TG6 IgA antibody level was further reduced in the AGA-
positive NCGS patient (42.4 vs 38 U/ml – 10% reduction), whereas the antibody level 
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was mildly increased in one of  AGA-positive no-NCGS patients (120 vs 131,5 U/ml – 
10% increase). Subsequent evaluation was not available for the other AGA-positive no-
NCGS patient who tested positive for TG6 IgA, because he decided to exit the study 
after the first follow-up visit.  
As for the determination of  TG6 IgG antibodies (Figure 16), differences in mean TG6 
IgG levels were not statistically significant in 3 different groups, neither at recruitment 
(mean concentration 10.68±6.17 I.U./ml, 10.98±7.87 I.U./ml, 6.83±2.09 I.U./ml, in 
AGA-positive NCGS patients, AGA-positive no-NCGS and AGA-negative patients, 
respectively), nor within the follow-up period (mean concentration at the first follow-up 
visit: 12.78±5.86 I.U./ml, 10.71±10.02 I.U./ml, 5.20±3.06 I.U./ml; mean concentration 
at the second follow-up visit: 10.43±7.32 I.U./ml, 10.03±8.89 I.U./ml, 5.77±4.64 
I.U./ml). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. TG6 IgG levels at recruitment and within the follow-up period. All patients 
were on normal, gluten-containing diet at recruitment. At follow-up visit 1, AGA-
positive patients were on gluten-free diet, AGA-negative patients on gluten-containing 
diet. At follow-up visit 2, all AGA-positive patients were on gluten-containing diet 
(gluten challenge), whereas AGA-negative patients continued on gluten-containing diet. 
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According to the reference values indicated by the manufacturers of  the commercial 
ELISA test, all patients tested negative for TG6 IgG antibodies, both at recruitment and 
within the follow-up period (Table 11).  
 
Table 11. Patients who tested positive to TG6 antibodies. 
 
  AGA-positive pts AGA-negative pts 
  NCGS no-NCGS All All 
  N. pts (%) N. pts (%) N. pts (%) N. pts (%) 
    
 
    
Positive to TG6 IgA 1/6 (17%) 2/5 (40%) 3/11 (27%) 0/6 (0%) 
Positive to TG6 IgG 0/6 (0%) 0/5 (0%) 0/11 (0%) 0/6 (0%) 
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CHAPTER IV: DISCUSSION 
 
4.1 Non-celiac Gluten Sensitivity in children with headache 
 
This study suggests that it is worth exploring the presence of  gluten-related diseases in 
subjects with headache. 
We found that about 50% children and adolescents, who were evaluated for primary 
headache in a specialized referral center, tested positive for native anti-gliadin antibodies. 
Thus, the estimated prevalence of  AGA-positivity resulted about 5-fold higher in this 
cohort than in the general population, according to published data [Volta 2008, Volta 
2012, Caio 2014, Catassi 2015]. The prevalence of  AGA-positivity was about 2-fold 
higher in children with headache than in general population even when considering cut-
off  values of  AGA tests for celiac disease, which were fixed at 50 I.U./ml, instead of  25 
I.U./ml, for the commercial ELISA test we used for AGA IgG determination. 
Conversely, none of  the subjects in this cohort had serological markers for celiac 
disease. 
Our findings are consistent with previous data reporting a 4- to 10-fold higher 
prevalence of  markers of  gluten-related disorders or ascertained celiac disease and 
NCGS, in headache patients than in general population, even though celiac disease 
appeared to be less prevalent in our cohort than in other headache pediatric cohorts, 
where it was estimated about 5% [Gabrielli 2003, Lionetti 2009, Lionetti 2010, 
Dimitrova 2013]. 
When the diagnostic algorithm for NCGS was applied, the prevalence of  the disease in 
our cohort of  AGA-positive pediatric headache patients was 55%. This is a quite 
elevated figure, possibly influenced by lack of  blindness for patients and physicians in 
gluten withdrawal or gluten challenge. However, in the study design we considered that 
our increased duration of  both phases, 2-fold longer than in the most recently proposed 
diagnostic algorithm, could consent a better evaluation of  the clinical course for 
fluctuating symptoms such as headache, and reasonably reduce the impact of  placebo 
and nocebo effects. Indeed, response to placebo is high in acute headache attacks, 
whereas the placebo effect in chronic headache remission is smaller and reported to be 
approximately one patient in four [Gabrielli 2003]. 
As for the clinical picture, we were not able to identify any headache features or 
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migraine-associated syndromes which might be typical for AGA-positive, NCGS 
patients. Conversely, we noted that gastrointestinal symptoms occurred more frequently 
in these patients (50%) than in AGA-positive patients without NCGS or in AGA-
negative subjects, being gastrointestinal complaints similarly prevalent in the latter 2 
groups (20% and 17%, respectively). Extra-intestinal symptoms other than headache 
were more frequent in AGA-positive patients, and very similar to those reported in 
almost all published NCGS cohorts, but they could not identify NCGS patients in the 
AGA-positive group [Catassi 2013, Volta 2014, Volta 2015]. Personal and family history 
for allergy was reported in about one patient out 3 AGA-positive NCGS subjects, and 
this finding is consistent with literature data [Volta 2014]; nevertheless, a similar figure 
was found in AGA-positive no-NCGS in this cohort, being not a key factor for NCGS 
again. No one had autoimmune diseases in NCGS patients in this headache cohort. In 
fact, autoimmune disorders seem to occur rarely in NCGS patients [Volta 2014]. 
 
4.2 Gene expression profiles in peripheral blood mononuclear cells from headache, 
NCGS patients 
 
Previous studies from collaborators to this research project provided important 
information on the pathogenetic mechanisms involved in celiac disease [Zanoni 2006, 
Dolcino 2013]. Data on etio-pathogenesis of  NCGS are preliminary and conflicting. 
Some research groups hypothesized a primary role of  the innate immune system, 
without any relevant involvement of  the adaptive immune response [Sapone 2011, 
Shuppan 2015]; other authors observed that expression of  IFNγ increased in duodenal 
mucosa after challenge with gluten, thus supporting a possible pathogenic role for 
adaptive immunity in this syndrome [Brottveit 2013]. A third line of  research considered 
gastrointestinal symptoms as independent from immunologic mechanisms, and possibly 
due to fermentation of  poorly absorbable molecules in foods [Biesiekierski 2013]. 
From the present analysis, genes belonging to functional classes of  immune response, 
both innate and adaptive, resulted modulated in the active phase of  NCGS. The gene 
expression profiling documented up-regulation of  a high number of  genes related to T- 
and B-lymphocyte activation and, even more interestingly, up-regulation of  genes related 
to Th17 cell subset and type I Interferon response. These findings are in line with  
experimental data by Brottveit and colleagues, and provide further evidence for a major 
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role of  adaptive immune response in NCGS. Notably, both type I IFN-driven 
inflammation and activation of  Th17 pathway are primarily involved in chronic 
inflammatory disorders of  the gut, such as Crohn disease, and in systemic autoimmune 
diseases, e.g. systemic lupus erythematosus, Sjogren’s Syndrome, and rheumatoid 
arthritis [Eken 2014, De Jong 2015, Ghodke-Puranik 2015, Nezos 2015]. Moreover, 
type I Interferon is the proximate driver of  the tissue damage resulting in villous 
atrophy in celiac disease, and a role of  Th17 cell subset has been hypothesized for this 
disorder [Mazzarella 2015]. 
In our cohort of  NCGS patients IL24, IL32, TNFRSF25 and CTLA-4 genes of  the “T-
lymphocyte activation” cluster were up-regulated. Notably, many of  these gene products 
are shown to be associated with chronic inflammatory and autoimmune disorders.  
IL-24 is upregulated in T cells, when c-Jun is overexpressed after an activating stimulus, 
and induces secretion of  IL-6, TNF-α and INF-γ at high levels. A body of  evidence 
accounts for a role of  IL-24 in autoimmune diseases such as psoriasis, rheumatoid 
arthritis and spondylo-arthropathies [Menezes 2014].  
IL-32 is expressed in NK cells and T lymphocytes after stimulation with TNFα and IL-
23, and induces the differentiation of  monocytes into macrophage-like cells which 
secrete pro-inflammatory cytokines such as IL-6 and TNFα. IL-32 also induces 
activation of  dendritic cells leading to an increased production of  IL-12 and IL-6, which 
are Th1- and Th17-polarizing cytokines, and the production of  this cytokine is 
associated with several inflammatory diseases, including rheumatoid arthritis and 
intestinal chronic inflammation [Xu 2013, Joosten 2013].  
TNFRSF25, also known as DR3, is expressed in NK cells and T cells, particularly on 
Th17 cells, and it is enhanced upon cell activation. Since the ligand of  DR3 is induced 
by inflammatory cytokines or TLR ligands, its interaction with DR3 represents a key 
event connecting innate immune responses to adaptive immune responses, and it is 
critically involved in the induction of  autoimmune and inflammatory diseases, such as 
rheumatoid arthritis and Crohn disease [Aiba 2013].  
CTLA-4 is a type I glycoprotein on the surface of  activated T-cells, which is a B7-
binding protein. The function of  CTLA-4 is attenuation of  ongoing immune responses, 
both for cellular and humoral immune responses. The CTLA-4 gene is able to generate 
messenger RNA for a full-length isoform (flCTLA-4) and a soluble form (sCTLA-4), 
which originates from alternative splicing and is found in the serum. The blockade of  
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B7/CTLA-4 interaction exacerbates autoimmune diseases in animal models. The soluble 
CTLA-4 is able to decrease in vitro proliferation of  T-cells and production of  IFN𝛾�, 
whereas it increases anti-inflammatory cytokines, such as TGF-𝛽�and IL-10. Immuno-
regulatory functions of  sCTLA-4 appear to be dependent on the activation state of  
cells. Since resting T-cells express sCTLA-4 but not flCTLA4, sCTLA4 inhibits B7–
CD28 interaction and sustains T-cell resting state; when flCTLA4 is overexpressed after 
T-cell activation, sCTLA4 interferes with B7–flCTLA4 interaction, blocks the flCTLA4 
inhibitory pathway, and finally results in a sustained T-cell activation [Saverino 2007, 
Simone 2014]. This regulatory pathway may be dependent on the duration of  the 
activating stimulus, as documented by in vitro experimental data: sCTLA-4 arrests 
lymphocyte proliferation when it is added within 24 hours, but it leads to a sustained 
lymphocyte proliferation if  added after 24 hours [Saverino 2007]. Such an effect, we 
argue, may be primarily directed to control acute inflammatory states, e.g. infectious 
diseases, and provide an explanation for high levels of  sCTLA-4 in chronic 
inflammatory disorders. In fact, increased concentrations of  sCTLA-4 were observed in 
patients with celiac disease, thyroid autoimmune diseases, type 1 diabetes, systemic 
sclerosis, and systemic lupus erythematosus, but also in patients with allergy or 
neoplastic disorders [Saverino 2007, Erfani 2010, Simone 2014]. The highest sCTLA-4 
levels were measured in the active phase of  the disease in the majority of  published case 
series, but a positive correlation with symptom severity was not confirmed. Interestingly, 
sCTLA-4 levels markedly decreased on gluten-free diet in patients with celiac disease 
[Simone 2009] and also in our headache AGA-positive cohort, providing evidence for 
sCTLA-4 as a biomarker of  gluten sensitization which is modulated by trigger 
withdrawal. 
As for the Th17 compartment, we observed that 9 genes, including IL6ST, STAT6, 
STAT5B and SOCS3, were up-regulated. The IL6ST protein, also known as gp130, is 
the beta-receptor for cytokines of  the IL-6 family which binds to the complex  
IL-6R/IL-6 and starts the signaling cascade, which involves the Jak/STAT pathway; at 
the same time, the negative feedback regulator SOCS3 is transcriptionally up-regulated 
and drives to degradation of  gp130 [Yao 2014, Garbers 2015]. T lymphocytes 
stimulated by IL-6 differentiate into Th17 cells, and this process is sustained in time 
[Calabrese 2014]. A body of  evidence shows that a deregulated cytokine signaling via 
gp130 is associated with chronic inflammation and autoimmune diseases (e.g., 
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rheumatoid arthritis and inflammatory bowel diseases) [Gabers 2015]. Therefore, the 
evidence for up-regulation of  genes primarily involved in IL-6 signaling pathways, at 
different levels, in our cohort of  headache patients, may be in favor of  a pathogenic role 
of  Th17 cells in NCGS.    
Even more interestingly, NCGS patients also showed up-regulation of  type I Interferon  
inducible genes (e.g. IRF5, IRF3, Ly-9), thus displaying a type I IFN signature. IRFs are 
transcriptional regulators of  the production of  type I Interferons (INFs). Type I IFNs 
drive the immune response polarizing T cells to a Th1 phenotype, in order to control 
viral infections. Interferon Regulatory Factor 5 (IRF5) is extremely important for 
increased and prolonged TNF production, and “gain of  function” IRF5 gene mutations 
have been associated with susceptibility to autoimmune diseases, such as systemic lupus 
erythematosus and inflammatory bowel diseases [Eames 2016]. Interferon Regulatory 
Factor 3 (IRF3) plays a role in Th17 cell development and function, as suggested by in 
vitro impaired IL-17 production in IRF3-deficient cells [Fitzgerald 2014]. Ly9 is expressed 
on T and B lymphocytes and regulates lymphocyte development and survival, 
cytotoxicity and humoral immunity, thus exerting crucial immunomodulatory functions. 
Moreover, it acts as an inhibitory receptor of  IFNγ-producing CD4+ T cells. A role for 
Ly9 in the maintenance of  immune cell tolerance is confirmed by experimental data in 
Ly9-deficient mice, which spontaneously develop features of  systemic autoimmunity. 
Alike for CTLA-4 gene, up-regulation of  LY-9 gene in NCGS patients would be 
consistent with activated immunomodulatory mechanisms meant to attenuate the 
ongoing immune response [De Salort 2013]. 
The transcriptional modulation of  genes related to the “Response to INFγ” cluster, 
namely up-regulation of  CD84 and down-regulation of  SLAMF8 genes, seems in line 
with observations above. Up-regulated CD84 in T-, B-, and dendritic cells increases 
activation of  these cells [Veillette 2010]. Instead, SLAMF8 is a surface receptor which 
modulates macrophage functions when it is induced by cell exposure to INFγ and 
dampens an ongoing innate immune response [Wang 2012]. The down-regulation of  this 
receptor, as we observed in NCGS patients, would presumably lead to a prolonged 
activation of  innate immune responses. Coherently, the MARCO gene, which codes for 
a macrophage scavenger receptor increasing phagocytosis after repetitive stimulation in 
order to protect hosts from excessive inflammation as documented by Jing et al. [2013], 
resulted down-regulated in our cohort of  NCGS patients. 
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A number of  transcripts involved in B cell and NK cell activity were modulated in this 
cohort of  NCGS patients, thus suggesting a concomitant activation of  this cell subset. 
Among them CLEC2D, also named LLT1, and the Leucocyte Immunoglobulin-like 
Receptors (LILRs) deserve further discussion.  
LLT1 is expressed on Toll-like receptor-activated plasmacytoid dendritic cells, but also 
on activated B-, T- and NK cells when they are stimulated with IFNγ in a Th1-
polarizing environment. LLT1 in turn increases IFNγ secretion by T cells, and IL-17 
secretion by Th17 cells. Thus, the interaction of  LLT1 with its receptor may participate 
in the switch from innate to adaptive immunity and regulate both innate and adaptive 
immune responses [Germain 2011]. The LLT gene was up-regulated in NCGS headache 
patients, thus providing evidence for a key role of  Th1 and Th17 cell activation in this 
disorder. 
LILRs are predominantly expressed on myelo-monocytic cells and B cells, interact with 
self-proteins and modulate dendritic cell activation status, antigen-presenting functions 
and their capacity to elicit T-cell responses. High levels of  LILRB2 and LILRB4 
decrease the expression of  costimulatory proteins, hindering dendritic cells’ ability to 
activate Th cells. LILRA2 engagement inhibits dendritic cell differentiation and antigen 
presentation, LILRA4 negatively regulates the secretion of  type I Interferons by 
plasmacytoid dendritic cells. Notably, all these genes were down-regulated in NCGS 
patients, providing further evidence for an ongoing, predominantly type I INF-driven, 
immune response. 
In a physiopathological perspective, the gene expression profile in headache NCGS 
patients is suggestive for a type I Interferon response - related syndrome. In this 
context, symptoms such as headache, fatigue, “foggy mind”, and “lack of  well-being”, 
so frequently reported by these patients, might be attributable to a “sickness behavior” 
phenomenon, alike it is well-known to occur in systemic inflammatory conditions 
[Maier 1998, Watkins 2000, Quan 2008, Benson 2012, Poon 2015]. 
However, since the great majority of  patients in this cohort also had family antecedents 
for headache, we can assume that this systemic inflammatory environment may 
contribute to potentiate, in genetically predisposed subjects, those neuro-inflammatory 
mechanisms responsible for the sensitization of  nociceptive second-order neurons, a 
phenomenon which is well-known to occur in patients suffering from recurrent 
headaches and leads to chronicization of  headache [Bendtsen 2011, Burstein 2015]. 
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4.3 Soluble mediators in sera and TG6 antibodies in headache patients 
 
We found that serum levels of  soluble CTLA-4 were significantly higher in headache 
AGA-positive patients than in AGA-negative subjects, and that sCTLA-4 levels 
markedly decreased on gluten-free diet in all subjects, despite NCGS diagnosis was not 
confirmed in a subgroup of  them. AGA-negative patients had very low levels of  
sCTLA-4, which were nearly unchanged on a normal, gluten-containing diet. Similar 
effects of  GFD on serum sCTLA4 levels were reported by Simone and colleagues 
[2009] on a cohort of  patients with celiac disease, although these authors found that 
levels of  sCTLA-4 were positively correlated with the severity of  enteropathy. 
Conversely, our findings are consistent with data from patients with autoimmune 
thyroid diseases or breast cancer, where no correlation between sCTLA-4 levels and 
disease stage or severity was found [Saverino 2007, Erfani 2010].    
Therefore, although sCTLA-4 cannot be considered a predictive biomarker for 
confirmed NCGS, high levels of  this soluble mediator might represent a clue for an 
ongoing inflammatory response related to gluten ingestion and adaptive immune 
response activation. Unfortunately, neither sCD25 nor sgp130 levels in sera could add 
any useful information, at least in this cohort of  patients. 
Finally, we observed that both patients who had high levels of  TG6 antibodies in sera 
did not display clinical amelioration on a 3 months - period on gluten-free diet. 
Therefore, we speculate that a longer duration of  the dietary treatment, maybe 6-12 
months as recommended for gluten ataxia, might be requested for headache patients 
who test positive for TG6 antibodies, in order to better evaluate a gluten-related 
disorder. 
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CONCLUSIONS 
 
The present work provides evidence for considering the diagnostic hypothesis of  Non-
celiac Gluten Sensitivity in children and adolescents with recurrent headaches fully 
satisfying criteria for primary headaches.  
Laboratory data from NCGS patients in this cohort suggest the existence of  an 
activated immune response with a type I Interferon signature. High levels of  soluble 
CTLA-4 in serum in headache AGA-positive patients could be a further clue for gluten 
sensitization and adaptive immune response activation. 
The presence of  TG6 antibodies in sera may predict a poor clinical response to gluten-
free diet upon a 3 months – period, thus justifying a gluten-free dietary treatment for 6-
12 months at least. 
Further investigation in larger series of  patients is needed to validate these preliminary 
results. Histo-pathological studies on duodenal specimens might be useful to evaluate 
local immune response, and to explore the role of  mucosal innate lymphoid cell 
compartment and inter-relationships between these innate immunity cells and other 
actors of  the immune response. 
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LIST OF ABBREVIATIONS FREQUENTLY USED IN THE TEXT 
 
AGA: native anti-gliadin antibodies 
AGA-positive NCGS patient: patient who tested positive for AGA and had the diagnosis 
of Non-celiac Gluten Sensitivity confirmed 
AGA-positive no-NCGS patient: patient who tested positive for AGA and had the 
diagnosis of Non-celiac Gluten Sensitivity excluded 
AGA-negative patient: patient who tested negative for AGA 
CD: Celiac disease 
CBCL: Child Behavior Checklist 
DH: Dermatitis Herpetiformis 
ELISA: enzyme-linked immunosorbent assay 
EMA: anti-endomysial antibodies 
GA: Gluten Ataxia 
GFD: gluten-free diet 
ICHD: International Classification of Headache Disorders 
IELs: intraepithelial lymphocytes 
IFN: Interferon 
IL-6: Interleukin-6 
IL-17: Interleukin-17 
MIDAS: Migraine Disability Score  
NCGS: Non-celiac Gluten Sensitivity 
PBMCs: Peripheral blood mononuclear cells 
sCD25: soluble form of IL-2 Receptor α-Chain 
sCTLA-4: soluble form of Cytotoxic T-Lymphocyte Antigen 4 
sgp130: soluble form of Glycoprotein 130 (also known as IL6ST) 
TGA: anti-tissue transglutaminase 2 (intestinal transglutaminase) antibodies 
TG3: tranglutaminase 3 (epidermal transglutaminase)  
TG6: tranglutaminase 6 (brain transglutaminase) 
Th1: T helper 1 lymphocyte 
Th17: T helper 17 lymphocyte 
TNF: Tumor necrosis factor 
TTH: Tension-type headache 
 
  
  
73 
 
ACKNOWLEDGMENTS 
 
My grateful acknowledgments to: 
 
Dr. Giovanna Zanoni (Dept. Medicine, Verona University) for invaluable supervision during 
the PhD course and suggestions in conceiving and development of the research project. 
 
Prof. Antonio Puccetti (DIMES, Genova University) and Claudio Lunardi (Dept. Medicine, 
Verona University) for their support in conceiving experiments and helpful discussion in the 
data analysis phase. 
 
Prof. Marco Chilosi and Dr. Paola Capelli (Dept. Diagnostics and Public Health, Verona 
University) for their support in biopsy examinations and helpful discussion. 
 
Mr. Ruggero Beri (Dept. Medicine, Verona University) for isolation of  peripheral blood 
mononuclear cells. 
 
Dr. Marzia Dolcino (DIMES, Genova University), who performed experiments of gene 
expression profiling. 
 
Dr. Daniele Saverino (DIMES, Genova University), Dr. Giulio Fracasso and Dr. Stefano 
Ugel (Dept. Medicine, Verona University), who provided their expert technical assistance 
and performed ELISA tests. 
 
Prof. Bernardo Dalla Bernardina and Prof. Vincenzo Bronte, who shared their experience in 
the field and provided the opportunity to work at this research project. 
 
Mrs. Oretta Gabrielli, Elena Chiesa and Virginia Adami (Immunology Unit, University 
Hospital of Verona) for their technical assistance, every day in these 3 years.  
 
All patients and their families, who participated in the research project. 
 
